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Pancreatic cancer is the fourth most common cause of cancer fatality in American 
men and women with a less than 5% survival rate. Currently, if diagnosed early, surgical 
resection remains the only viable cure. However, only 20% of pancreatic cancer patients 
meet these criteria. It is therefore necessary to discover new therapies or therapeutic 
combinations in order to impact significantly this deadly disease. The anti-metabolite 
agent Gemcitabine is currently being employed to treat pancreatic cancer. While Gem-
citabine has shown significant benefit in clinical applications, its ability to more than 
modestly impact pancreatic cancer is limited. It has been speculated that combinatory 
treatments using Gemcitabine could improve survival rates. Survivin, a member of the 
inhibitor of apoptosis (IAP) protein family, is expressed in virtually all cancer cells, but 
not detectable in most normal cells outside of development. Mutation of Survivin’s Thre-
onine 34 to Alanine (Survivin-T34A) abolishes a phosphorylation site for p34cdc2-cyclin 
B1 resulting in the initiation of the mitochondrial apoptotic pathway in cancer cells with 
little to no direct effects on normal cells. The possibility that targeting Survivin in this 
manner may provide a novel approach for selective cancer gene therapy has yet to be ful-
ly evaluated. We have recently described that cells generated to express a stable form of 
the mutant protein, released this Survivin-T34A to the conditioned medium. When this 
xiv 
conditioned medium was collected and deposited on naive tumor cells, conditioned me-
dium containing Survivin-T34A was as effective as chemotherapy in induction of tumor 
cell apoptosis. When combined with other forms of genotoxic stress, Survivin-T34A po-
tentiated their killing effects. We further determined that Survivin-T34A is trafficked by 
microvesicles called exosomes, which are released into the conditioned media. We 
showed strong evidence that exosomes containing Survivin-T34A elicited cellular death 
and synergistically enhanced cellular death during combination with low doses of Gem-
citabine and we propose that these findings may lead to novel modalities for cancer 
therapies. This dissertation provides the rational for Survivin-T34A’s potential as a thera-
peutic. Next, we provide evidence that extracellular Survivin-T34A can elicit its anti-
tumor effects on treated cells. Finally, I show that extracellular Survivin-T34A is found 
in exosomes. 
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Abstract 
  The inhibitor of apoptosis (IAP) protein Survivin’s Threonine 34 to Alanine mu-
tation abolishes a phosphorylation site for p34cdc2-cyclin B1 resulting in the initiation of 
the mitochondrial apoptotic pathway in cancer cells yet has little known direct effects on 
normal cells. The possibility that targeting Survivin in this way may provide a novel ap-
proach for selective cancer gene therapy has yet to be fully evaluated. Though a flurry of 
work was undertaken in the late 90s and early 2000s, only minor advances on this mutant 
have recently taken place. We recently described that cells generated to express a stable 
form of the mutant protein, released this Survivin-T34A to the conditioned medium. 
When this conditioned medium was collected and deposited on naive tumor cells, condi-
tioned medium T34A was as effective as some chemotherapeutics in induction of tumor 
cell apoptosis and when combined with other forms of genotoxic stressors, potentiated 
their killing effects. In addition to determining the therapeutic dose and the duration of 
drug therapy required at the disease site, a better understanding of other key factors is al-
so important. These include knowledge of target cell populations, cell-surface receptors, 
changes that occur in the target tissue at the molecular and cellular level with progression 
of the disease, and the mechanism and site of therapeutic action. 
 
  
3 
Introduction 
Survivin is Important in Cancer 
  Apoptosis is a physiological cell suicide program that is critical for the develop-
ment and maintenance of healthy tissues (Deveraux and Reed 1999). The evasion of 
apoptosis, as identified by Hanahan and Weinberg, is a primary characteristic of human 
cancer (Hanahan and Weinberg 2000) with proteins involved in its control of significant 
biological interest as they could prove to be important targets for therapy development. 
The inhibitor of apoptosis (IAP) family consists of proteins with proven ability to inhibit 
apoptosis, although much of how this works mechanistically is still to be revealed. Sur-
vivin is an important IAP because its expression is among the most tumor specific of all 
human gene products (Velculescu, Madden et al. 1999, Reed 2001). It has been classified 
as a bifunctional protein as it can inhibit apoptosis and cell cycle (Li, Ambrosini et al. 
1998). More specifically, Survivin’s promoter exhibits M phase inducible transactivation 
and in HeLa cells, both Survivin protein and mRNA are upregulated at G2/M phase of the 
cell cycle (Li, Ambrosini et al. 1998). Survivin expression is enhanced during embryonic 
and fetal development, but not in terminally differentiated normal tissue (Li 2003). Its 
expression has also been seen in virtually every type of human cancer (Andersen, Svane 
et al. 2007), making Survivin an attractive protein in the study of cancer pathophysiology, 
drug discovery and medical diagnosis. Our laboratory has recently shown that cancer 
cells release Survivin into the extracellular space (Khan, Aspe et al. 2009) packaged in 
small 50-150 nm vesicles called exosomes (Khan, Jutzy et al. 2010). This is significant as 
it may reveal new mechanisms into how cancer cells communicate with one another and 
how they affect the tumor microenvironment and we hope that this discovery may pro-
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vide other options for targeted therapy. However, this discovery begs for studies about 
why and how Survivin is packaged within exosomes as well as how Survivin from exo-
somes is utilized by the recipient cells as well as what are the effects of exosomal 
Survivin on normal human cells? 
  Survivin physically associates with and is phosphorylated on its 34 Threonine 
(Thr34) by the cyclin-dependent kinase p34(cdc2)–cyclin B1 protein complex (O'Connor, 
Grossman et al. 2000). Loss of Thr34 phosphorylation results in dissociation of the caspa-
se-9-Survivin protein complex and caspase-dependent apoptosis (O'Connor, Grossman et 
al. 2000, Mesri, Wall et al. 2001, Wall, O'Connor et al. 2003). Initially, Thr34 through 
site-directed mutagenesis was changed to Ala (T34A) as a non-phosphorylated mimic of 
Survivin (O'Connor, Grossman et al. 2000). When replication-deficient adenoviruses en-
coding this Survivin-T34A mutant were produced and used to infect cancer cell lines, 
spontaneous apoptosis resulted. In contrast, the viability of normal human cells including 
fibroblasts, endothelium and smooth muscle cells were unaffected (Mesri, Wall et al. 
2001). In studies analyzing normal human oral mucosa, oral submucosa fibrosis and oral 
squamous cell carcinomas (Zhou, Li et al. 2008), a gradation from no Survivin Thr34 
phosphorylation in normal to significantly enhanced amounts of phosphorylated Survivin 
Thr34 in the cancer tissues was recorded. Furthermore, phosphorylated Thr34 and 
p34(cdc2) kinase expression was not detected in normal tissue samples but increased with 
advancing stages in the cancer tissue samples (Zhou, Li et al. 2008). Agents that elevate 
p34(cdc2) kinase activity during spindle checkpoint activation drive increased Survivin 
expression and cancer cell viability (O'Connor, Wall et al. 2002) resulting in limited anti-
cancer effects. Pharmacologic, genetic, or molecular ablation of p34(cdc2) kinase after 
5 
microtubule stabilization resulted in apoptosis independent of p53, suppression of tumor 
growth, and indefinite survival without toxicity in mice (O'Connor, Wall et al. 2002). 
Taken together, the ablation of Survivin-dependent apoptosis inhibition could improve 
the efficacy of many agents used to treat cancer. 
  One of the most daunting questions in any gene-based approach for cancer treat-
ment is in the method of delivery. We have recently shown that Survivin exists in a novel 
extracellular pool in tumor cells. Furthermore, we have constructed stable cell lines that 
provide the extracellular pool with either wild-type Survivin or dominant-negative mutant 
Survivin (T34A) (Khan, Aspe et al. 2009). Cancer cells grown in the conditioned medium 
taken from wild-type Survivin expressing cells absorbed Survivin and experienced en-
hanced protection against genotoxic stress as well as exhibited an increased replicative 
and invasive potential (Khan, Aspe et al. 2009). Alternatively, cancer cells grown in con-
ditioned medium from T34A cells began to apoptose through a caspase-2- and caspase-9-
dependent pathway that was further enhanced by the addition of chemo- and radiothera-
peutic modalities (Khan, Aspe et al. 2009), We believe that this extracellular Survivin-
T34A could be used as a possible “White Knight” to Survivin’s “dark family”. The fol-
lowing sections detail T34A’s journey as a novel potential cancer therapeutic. The studies 
above have already provided impetus for further studies on T34A, but there is still a lot 
unknown. The advancement of future T34A studies may provide a more comprehensive 
understanding of cancer and the potential of using T34A to battle it. 
 
6 
T34A Induces Apoptosis 
  What makes this Survivin-T34A mutant important as a potential therapeutic is 
that little or no toxicity has resulted from its treatment in vitro or in vivo (Wall, O'Connor 
et al. 2003, Yan, Thomas et al. 2006, Peng, Yang et al. 2008). T34A treated mice showed 
significantly longer survival rates compared to control mice as well as had no pathologic 
changes in major organs (Li, Zhao et al. 2009). More specifically, tumor cells treated in 
vitro with T34A exhibited reduced cell survival that was associated with morphological 
features of apoptosis (Mesri, Wall et al. 2001, Blanc-Brude, Mesri et al. 2003, McKay, 
Bell et al. 2003, Fukuda and Pelus 2004, Liu, Brouha et al. 2004, Wang, Fukuda et al. 
2004, Zhang, Mukherjee et al. 2005, Ma, Zheng et al. 2006, Yan, Thomas et al. 2006, 
Peng, Yang et al. 2008, Zhang, Wang et al. 2008, Khan, Aspe et al. 2009, Shen, Liu et al. 
2009, Xiao, Chen et al. 2010, Yu, Wang et al. 2010). Studies of mouse-xenographs treat-
ed with Survivin-T34A concluded with significant tumor size reduction and increased 
animal survival rates (Blanc-Brude, Mesri et al. 2003, Yan, Thomas et al. 2006, Peng, 
Yang et al. 2008, Li, Zhao et al. 2009, Yu, Wang et al. 2010) except in mice subcutane-
ously injected with the IGROV1 ovarian carcinoma cell line, where there were no 
significant differences between T34A infected tumors and controls (McKay, Bell et al. 
2003). These results may however be explained as IGROV1 cells do not express signifi-
cant levels of endogenous Survivin and T34A, as shown in normal, Survivin non-
expressing cells, does not induce apoptosis (Mesri, Wall et al. 2001). It was not until 
IGROV1 cells were infected with adenovirus-vector expressing caspase-3 (Ad-caspase-3) 
or co-infected with Ad-caspase-3 & Ad-T34A that tumor size was reduced and survival 
rates extended (McKay, Bell et al. 2003). It is of much interest that the adenoviruses used 
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in these studies upregulated survivin mRNA, as shown by RT-PCR, and concomitantly 
resulted in a half-fold reduction in another IAP, XIAP (McKay, Bell et al. 2003). Fur-
thermore, in melanoma cells that have been engineered to express an inducible Survivin-
T34A (Grossman, Kim et al. 2001), XIAP and the IAP Livin were cleaved upon T34A 
induction (Liu, Brouha et al. 2004). These reductions may in part be responsible for the 
more favorable outcomes observed in these studies. In contrast, it has been postulated 
that the transfection of cells may affect endogenous levels of XIAP, but there was no ef-
fect on XIAP protein levels following transfections using virus vector controls, Ad-
Survivin or Ad-T34A treatment (Mesri, Wall et al. 2001, McKay, Bell et al. 2003, Liu, 
Brouha et al. 2004). There were also no changes in other IAPs or members of the Bcl-2 
family (Liu, Brouha et al. 2004). While Survivin-T34A may not affect endogenous levels 
of other IAPs, a Survivin-IAP (XIAP, cIAP1, and cIAP2) complex has been confirmed as 
well as suggestion for direct interaction between Survivin and XIAP through their BIR 
domains (Dohi, Okada et al. 2004). Furthermore, evidence that T34A can only kill cells 
expressing Survivin has been shown in its inability to kill normal human cells treated in 
vitro (Mesri, Wall et al. 2001, McNeish, Lopes et al. 2005) and in vivo (Mesri, Wall et al. 
2001, Yan, Thomas et al. 2006). However, T34A has shown significant killing affects in 
normal endothelial cells that express high levels of endogenous Survivin (Blanc-Brude, 
Mesri et al. 2003). Whether this is the result of some interaction between endogenous 
Survivin, other IAPs, and the T34A mutant or a competition between them for protein 
interactors is currently unknown. 
  Mechanistic examination of T34A-induced apoptosis revealed mitochondrial 
events that preceded caspase activation, including depolarization and the release of cyto-
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chrome c, AIF and Smac/DIABLO (Mesri, Wall et al. 2001, Blanc-Brude, Mesri et al. 
2003, Liu, Brouha et al. 2004, Ogura, Watanabe et al. 2008). Also, T34A treatment of 
melanoma cells has also been shown to involve Apaf-1, Mcl-1 and PARP cleavage 
(Blanc-Brude, Mesri et al. 2003, Liu, Brouha et al. 2004, Zhang, Wang et al. 2008). 
Stress-induced cytochrome c release results in apoptosome formation and caspase activa-
tion (Boya and Kroemer 2008), thus several groups have reported that caspase-3 may be 
important to T34A-induced apoptosis (Mesri, Wall et al. 2001, Blanc-Brude, Mesri et al. 
2003, McKay, Bell et al. 2003, Fukuda and Pelus 2004, Liu, Brouha et al. 2004, Wang, 
Fukuda et al. 2004, Barrett, Osborne et al. 2009). A significant increase in apoptosis was 
reported in ovarian carcinoma cells treated with T34A and caspase-3 in vivo and in vitro 
(McKay, Bell et al. 2003). We, however, working in cervical carcinoma HeLa cells, were 
unable to show cleavage of caspase-3 or caspase-8, though cleavage of caspase-9 and 
caspase-2 was recorded (Khan, Aspe et al. 2009). Further experiments revealed T34A-
induced a reduction in the proforms of caspase-2, caspase-7 and caspase-9, a cleavage of 
PARP and an induction of mitochondrial depolarization. Treatment with caspase inhibi-
tors, Z-DEVD-FMK and Z-VAD-FMK, has been shown to counter the effect of T34A 
treatment suggesting T34A-induced apoptosis may act through the caspase-dependent 
pathway (Liu, Brouha et al. 2004). Additionally, the earliest proapoptotic event observed 
in T34A treated cells was nuclear translocation of mitochondrial apoptosis-inducing fac-
tor AIF, which triggers both mitochondrial associated apoptosis and caspase-independent 
DNA fragmentation (Liu, Brouha et al. 2004). Taken together, Survivin-T34A targets the 
intrinsic (Kroemer and Pouyssegur 2008) or mitochondria-associated apoptotic pathway 
to induce most probably caspase-dependent and independent apoptosis (Figure 1).  
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Figure 1. Survivin-T34A induces apoptosis by modulating the intrinsic (mitochondrial) 
pathway of apoptosis. After the mitochondrial depolarization, mitochondrial proteins 
such as Cytochrome c and SMAC/Diablo which activate caspases as well as those that 
are caspase-independent such as AIF are released by way of transmembrane channels 
across the mitochondrial outer membrane. 
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the therapeutic strategy needed for targeting p53-associated 
stress-induced repair pathways in cancer.
Survivin Thr34 plays a role in cell 
cycle regulation
Survivin is a structurally unique IAP family protein that is 
expressed in mitosis in a cell cycle-dependent fashion and 
localized to components of the mitotic apparatus.5 Survivin 
has been described as bifunctional, in that it is involved in 
both inhibition of apoptosis and control of cell division.45,46 
In order to study the effect survivin phosphorylation at 
Thr34 had on cell division, the nonphosphorylatable T34A 
form of survivin was compared with T34E, which acts as 
a phosphomimetic.34 As a phosphomimetic, T34E assumes 
the role of a phosphorylated Thr34 and therefore mimics an 
activated survivin. T34A-treated cells grew two-fold faster 
than control cells, whereas T34E cells grew 2.5-fold slower. 
Depletion studies showed that only T34A was normally 
distributed and able to support cell proliferation, whereas 
T34E was not.
T34A T34A
Caspase-2
Caspase-9
Caspase-3
Caspase-7
Mcl-1
Mitochondrial
depolarization
Mitochondria
Bax
Cytochrome C
release
Apoptosome
XIAP
PARP
Apoptosis
cleavage
Smac/
DIABLO
AIF
Survivin
Mdm2
p53
Red – Activated protein
Green – Downregulated
– Translocation
Apaf-1
Figure 1 Survivin-T34A induces apoptosis by modulating the intrinsic (mitochondrial) pathway of apoptosis. After the mitochondrial depolarization, mitochondrial proteins 
that activate caspases, such as cytochrome c and Smac/Diablo, as well s those that are caspase independent, such as AIF, are released by way of transmembrane channels 
across the mitochondrial outer membrane.
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However, with the exception of one study (Shin, Sung et al. 2001), Survivin has not been 
shown to directly inhibit caspases and whether Survivin-T34A disrupts caspase activity 
has yet to be fully elucidated. We postulate that Survivin-T34A-induced apoptosis begins 
farther upstream in the intrinsic apoptotic pathway initiating mitochondrial depolarization 
as well as inhibition of IAPs known to directly inhibit caspases (e.g. XIAP-caspase-3). 
  The tumor suppressor gene, p53, has been widely studied and is known to induce 
apoptosis (Haldar, Negrini et al. 1994, Strobel, Swanson et al. 1996). As a transcription 
factor, p53 is activated by a variety of genotoxic and cytotoxic stresses. Upon activation, 
p53 prevents the proliferation of genetically compromised cells by regulating the expres-
sion of a battery of genes that initiate cell cycle arrest, apoptosis and DNA repair (Figure 
2) (Ashcroft and Vousden 1999). Transcriptionally, p53 activates Mdm2, which in turn 
targets p53 for ubiquitin proteasome-dependent degradation. In response to stress, a de-
crease in Mdm2 protein levels and/or its activity and the interaction between Mdm2 and 
p53 lead to p53 stabilization (Marine and Lozano). The relationship between Survivin 
and p53 may be important, as Survivin regulates cell division and inhibits apoptosis 
whereas p53 inhibits cell cycle progression and induces apoptosis (Wang, Fukuda et al. 
2004). Survivin was recently shown to be transcriptionally repressed by wild type p53 
and when overexpressed in cells sensitive to p53-dependent cell death, markedly inhibit-
ed apoptosis induced by ultraviolet light (Hoffman, Biade et al. 2002). 
  When cancer cells that had been stably transfected with Survivin-T34A were 
treated with the DNA damage-inducing Adriamycin, p53 protein levels were significantly  
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Figure 2. Survivin-T34A promotes p53-associated apoptosis. Upon activation, p53 pre-
vents the proliferation of genetically compromised cells by regulating the expression of a 
battery of genes that initiate cell cycle arrest, apoptosis, and DNA repair. Survivin disrup-
tion by T34A treatment of cancer cells resulted in increased p53 protein levels and 
proteasomal degradation of Mdm2. 
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elevated compared to DNA damage alone or when combined with stably transfected Sur-
vivin (Wang, Fukuda et al. 2004). Increased levels of p53 mRNA preceded the elevation 
in p53 protein levels seen with T34A-treated cells, suggesting that p53 may be directly 
upregulated by Survivin-T34A. Survivin disruption by Survivin-T34A also resulted in the 
degradation of Mdm2. Proteasome inhibition and caspase-3 inhibition blocked this Sur-
vivin-T34A-associated decrease in Mdm2 resulting in the stabilization of p53. Survivin-
T34A was not shown to affect mRNA levels of Mdm2 (Wang, Fukuda et al. 2004). Fur-
thermore, the p53 homologues TAp63, ∆Np63, TAp73 and ∆Np73 were analyzed for 
changes following Survivin-T34A treatment. The response of these p53 homologues is 
important because TAp63 and TAp73 both transactivate similar genes as p53, whereas 
the ∆Np63 and ∆Np73 function as antagonists to p53 and the TA-homologues (Yang, 
Kaghad et al. 1998, Irwin and Kaelin 2001, Yang, Kaghad et al. 2002). ∆Np63, TAp73 
and ∆Np73 were all decreased in response to Survivin-T34A, while TAp63 was not de-
tectable. These findings suggest that p53 transcription may be differentially regulated by 
Survivin-T34A (Wang, Fukuda et al. 2004). Taken together, the ability of Survivin-T34A 
to perturb the p53/Mdm2 feedback loop resulting in increasing levels of p53 and p53’s 
ability to then transcriptionally repress Survivin may prove to be just the therapeutic 
strategy needed for targeting p53-associated stress-induced repair pathways in cancer. 
 
Survivin Threonine 34 Plays a Role in Cell Cycle Regulation 
  Survivin is a structurally unique IAP family protein that is expressed in mitosis in 
a cell cycle-dependent fashion and localized to components of the mitotic apparatus (Li, 
Ambrosini et al. 1998). Survivin has been described as bifunctional, in that it is involved 
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in both inhibition of apoptosis and control of cell division (Altieri 2003, Altieri 2006). In 
order to study the effect Survivin phosphorylation at Thr34 had on cell division, the non-
phosphorylatable T34A form of Survivin was compared to T34E, which acts as a 
phosphomimetic (Barrett, Osborne et al. 2009). As a phosphomimetic, T34E assumes the 
role of a phosphorylated Thr34 and therefore mimics an activated Survivin. T34A-treated 
cells grew 2-fold faster than control cells while T34E cells grew 2.5-fold slower. Deple-
tion studies showed that only T34A was normally distributed and able to support cell 
proliferation while T34E could not. 
  Survivin has been known to be upregulated in G2/M of the cell cycle, but T34A’s 
ability to induce apoptosis is G2/M-independent (McKay, Bell et al. 2003). The cell cycle 
profile of T34A treated cells was normal while T34E treated cells had a significantly in-
creased G2/M population suggesting that cell division failed (Barrett, Osborne et al. 
2009). Furthermore, cancer cells which exhibited endogenous levels of functional Sur-
vivin, when treated with T34A showed significant mitotic index inhibition (Mesri, Wall 
et al. 2001), as well as reduction in colony formation (Khan, Aspe et al. 2009). Ultimate-
ly, when endogenous Survivin was depleted, T34A restored Survivin’s mitotic function 
while T34E was mitotically incompetent. We therefore conclude that phosphorylated 
Thr34 inhibits mitosis (Barrett, Osborne et al. 2009), but non-phosphorylated Survivin is 
important for mitosis. 
  T34A has been shown to decrease the proportion of cells in S-phase following S-
phase arrest (Fukuda and Pelus 2004). Evidence for Survivin-T34A regulation of chro-
mosomal passenger complexes and central spindle checkpoint during mitosis has been 
generated (Lens, Rodriguez et al. 2006). In this work, Survivin-T34A was also shown to 
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be able to restore the spindle checkpoint defect following mitosis arrest unlike the other 
non-wildtype forms as well as rescue the cells from cytokinesis failure (Lens, Rodriguez 
et al. 2006). These findings strongly suggest Survivin-T34A is a functional complement 
for endogenous Survivin. Because Survivin-T34A functionally behaves as Survivin, it 
can localize appropriately during mitosis and thus correctly colocalize Aurora B at the 
centromeres and midzone (Lens, Rodriguez et al. 2006, Barrett, Osborne et al. 2009), al-
lowing proper mitosis regulation. Further experiments show that Survivin-T34A correctly 
localizes BubR1 to the kinetochores and can restore localization of endogenous Boreal-
in/Dasra B to both centromeres and central spindles (Ruchaud, Carmena et al. 2007). 
Taken together, Survivin-T34A allows for the enhanced proliferative effects of Survivin 
while Survivin-T34E does not. This suggests that the non-phosphorylated Survivin Thr34 
(T34A) accounts for cellular proliferation as opposed to the phosphorylated Survivin 
Thr34 (T34E). Also, contrasting Survivin Thr34 for its cytoprotective activity revealed that 
T34E is responsible for the antiapoptotic characteristics whereas T34A allows for caspase 
activation and induced apoptosis (Barrett, Osborne et al. 2009). 
 
T34A Opposes Classical Cancer Characteristics 
  Angiogenesis is crucial for cell survival and function and without it tumor cells 
are not able to obtain oxygen and nutrients. Targeting tumor angiogenesis is a relatively 
new therapeutic strategy and it is believed that if the tumor’s oxygen and nutrient supply 
is limited, tumor growth and development will be inhibited and may result in apoptosis. 
Survivin-T34A treatment of tumor-bearing mice resulted in inhibited tumor-induced an-
giogenesis and increased apoptosis (Peng, Yang et al. 2008, Li, Zhao et al. 2009, Shan, 
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Wang et al. 2010, Yu, Wang et al. 2010). Tumor sections taken from human breast cancer 
transplants in mice were stained with anti-CD31 antibody to determine microvessel den-
sity (Pan, Peng et al. 2010). Survivin-T34A treated groups showed significantly reduced 
microvessel density compared to controls (Peng, Yang et al. 2008). In vivo results 
showed T34A-induced apoptotic characteristics in murine endothelial cells as well as de-
creased new vessel formation when compared to control mice (Blanc-Brude, Mesri et al. 
2003, Peng, Yang et al. 2008). Furthermore, experiments using CT26 colorectal cancer 
cells showed similar results (Li, Zhao et al. 2009). It is still unknown how Survivin-T34A 
treatment reduces tissue staining for the angiogenesis marker CD31. The elucidation of 
this mechanism may provide insight into this tumor-acquired capability. Survivin has 
been shown to be upregulated by vascular endothelial growth factor (VEGF) (Blanc-
Brude, Mesri et al. 2003), an important promoter of angiogenesis. Perhaps, Survivin 
regulation by VEGF promotes angiogenesis by protecting developing vessels from apop-
tosis. Therefore, Survivin-T34A inhibits VEGF’s promotion of angiogenesis, which may 
be mediated through loss of p53, activation of phosphatidylinositol 3’-kinase, or phos-
phorylation of signal transducers and activators of transcription 3 (Tran, Rak et al. 1999, 
O'Connor, Schechner et al. 2000, Papapetropoulos, Fulton et al. 2000, Mahboubi, Li et al. 
2001, Harfouche, Hassessian et al. 2002). 
  Once a tumor mass becomes constricted, cells acquire the ability to invade sur-
rounding tissue and metastasize to distant sites, which accounts for 90% of human cancer 
deaths (Hanahan and Weinberg 2000). The inhibition of Survivin using adenoviruses 
(Ad-T34A) or short hairpin RNA dramatically inhibited invasiveness of prostate cancer 
cells in the in vitro invasion assay, and spontaneous metastasis in the Dunning prostate 
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cancer in vivo model (Zhang, Coen et al. 2010). Treatment of subcutaneous breast cancer 
tumors in mice using T34A plasmids (Peng, Yang et al. 2008) or Ad-T34A (Mesri, Wall 
et al. 2001) inhibited metastasis of breast tumor cells from the primary tumor site to the 
lungs and peritoneum, respectively (Peng, Yang et al. 2008). Specifically, control treat-
ment groups were observed to have a greater number of metastatic nodules and structural 
destruction of pulmonary alveoli compared to the T34A treatment group in transplanted 
mice (Mesri, Wall et al. 2001, Peng, Yang et al. 2008). In light of the role metastasis 
plays in cancer death, T34A’s metastasis-inhibitory role is important as current therapeu-
tics offer limited capabilities. 
  Cancerous lesions promote tumor growth, motility, invasion and angiogenesis via 
oncogene-driven immunosuppressive leukocyte infiltrates (Melief 2008). T34A has been 
shown to enhance T lymphocyte activity against autologous tumor cells (Peng, Yang et 
al. 2008). In addition, T cells derived from mouse xenographs exhibited higher cytotoxi-
city against target tumor cells in T34A treated mice (Li, Zhao et al. 2009). Further studies 
revealed that adoptive transfer of CD8+ T lymphocytes, and not their CD4+ T lymphocyte 
counterparts, isolated from the spleen of T34A treated mice exhibited a decrease in tumor 
volume. Perhaps the treatment of tumor cells with T34A or with immune cells that have 
been primed by Survivin-T34A association will redress the immunosuppression associat-
ed with cancer. 
 
Translational Approaches and Obstacles 
  Given Survivin’s role in chemotherapy and radiation resistance (Mesri, Wall et al. 
2001, Wall, O'Connor et al. 2003, Chakravarti, Zhai et al. 2004, Fujie, Yamamoto et al. 
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2005, Zhang, Latham et al. 2005, Zhang, Mukherjee et al. 2005, Ferrario, Rucker et al. 
2007, Ogura, Watanabe et al. 2008) results using T34A would suggest its role is to pro-
mote sensitivity to chemotherapy and radiotherapy. In the first study to investigate 
T34A’s ability to enhance cancer cell chemosensitivity, transfected Survivin-T34A-
induced apoptosis was as effective as Taxol alone, whereas transfected Survivin-T34A 
cells enhanced Taxol-induced apoptosis (Mesri, Wall et al. 2001). Subsequent studies in-
volving other chemotherapeutics have also revealed enhanced apoptosis in T34A-
expressing cancer cells and xenograph models (Flutamide (Zhang, Latham et al. 2005), 
Paclitaxel (Zhang, Mukherjee et al. 2005)). Survivin-T34A combined with Adriamycin 
exhibited no added effect over Adriamycin alone (Mesri, Wall et al. 2001). This study 
was followed by studies designed to characterize phosphorylated Survivin Thr34’s protec-
tive role. Following Adriamycin treatment of tumor cells, p34(cdc2) was 
coimmunoprecipitated with Survivin. These findings suggest that p34(cdc2) phosphory-
lates Survivin on Thr34 following Adriamycin treatment thus protecting the cells against 
the chemotherapeutic. These results were correlated with elevated MPM-2 mitotic phos-
phoepitope expression (Wall, O'Connor et al. 2003). While Survivin-T34A combined 
with Adriamycin exhibited no added effect over Adriamycin alone, it may still be possi-
ble to synergistically enhance Adriamycin’s effect with pretreatment of Survivin-T34A. 
The same study further showed that increased doses of Flavopiridol treatment were asso-
ciated with suppression of Survivin Thr34 phosphorylation.  
  Human glioblastoma multiforme (GBM) cells were treated with adenoviral vec-
tors containing T34A or Survivin, in vivo and in vitro. No change was seen in normal 
cells treated with either Survivin form, but radiosensitivity was exhibited in T34A treated 
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cells compared to Survivin-treated or control cells. Several other studies have confirmed 
similar results suggesting that Survivin only affects radiosensitivity of tumors cells and 
radioresistance can be reduced by T34A treatment (Ferrario, Rucker et al. 2007, Ogura, 
Watanabe et al. 2008, Barrett, Osborne et al. 2009, Khan, Aspe et al. 2009, Yuan, Wang 
et al. 2010). Interestingly, when cancer cells were irradiated and then treated with T34A, 
radiosensitivity was enhanced even more (Chakravarti, Zhai et al. 2004). Enhanced radia-
tion sensitivity may be explained by cleavage and activation of caspase-3 in T34A treated 
cells. Caspase inhibitors, except those for caspase-9, have been able to reduce apoptotic 
phenotypes in X-irradiation of T34A-treated cells (Ogura, Watanabe et al. 2008). Radio-
sensitivity may also be induced via a caspase-independent mechanism (Chakravarti, Zhai 
et al. 2004). DNA double strand breakage was greater in T34A treated cells suggesting 
that T34A may interfere with the cell’s ability for DNA repair post irradiation 
(Chakravarti, Zhai et al. 2004). 
 
Conclusion 
  Survivin-T34A has a rich history, having been first utilized as a mimic of non-
phosphorylated Survivin, and now as a possible cancer therapeutic. It is full of potential 
as a molecular therapy because of its minimal toxicity and its ability to induce apoptosis 
and immune modulation while reducing angiogenesis, metastasis and cell cycle progres-
sion in Survivin expressing cells (Figure 3). With the discovery that T34A conditioned 
medium, taken from cells that overexpress and release Survivin-T34A to the extracellular 
space, is able to kill cancer cells in vitro (Khan, Aspe et al. 2009), we hope to further en-
hance the scientific data banks and pave new paths for clinical modalities and regimens. 
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For this to occur however, additional testing of this agent on normal tissues – specifically 
testing its myelosuppressive effects, will have to be completed. Also, additional studies to 
synergistically enhance chemo-and radiotherapies, whether in combination with or 
through Survivin-T34A pretreatment, must be accomplished. The knowledge that will 
make this possible includes: the elucidation of Survivin-T34A target cell populations, 
cell-surface receptors, changes that occur in the target tissue at the molecular and cellular 
level, the presence or development of resistance which could limit its use, the mechanism 
of therapeutic action, and its site of action. As Survivin and p53 are important opposing 
regulators of cancer, further research on their interactions and signaling pathways will 
likely provide specific clues for understanding this complicated relationship. 
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Figure 3. Survivin-T34A has therapeutic potential, as it has been shown to induce apop-
tosis and immune modulation while reducing angiogenesis, metastasis, and cell cycle 
progression in Survivin-expressing cells. 
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Abstract 
The tumor microenvironment is believed to be involved in development, growth, 
metastasis, and therapy resistance of many cancers. Here we show Survivin, a member of 
the inhibitor of apoptosis protein (IAP) family, implicated in apoptosis inhibition and the 
regulation of mitosis in cancer cells, exists in a novel extracellular pool in tumor cells. 
Furthermore, we have constructed stable cell lines that provide the extracellular pool with 
either wild-type Survivin (Surv-WT) or the previously described dominant-negative mu-
tant Survivin (Surv-T34A), which has proven pro-apoptotic effects in cancer cells but not 
in normal proliferating cells. Cancer cells grown in conditioned medium (CM) taken 
from Surv-WT cells absorbed Survivin and experienced enhanced protection against gen-
otoxic stresses. These cells also exhibited an increased replicative and metastatic 
potential, suggesting that Survivin in the tumor microenvironment may be directly asso-
ciated with malignant progression, further supporting Survivin's function in 
tumorigenesis. Alternatively, cancer cells grown in CM taken from the Surv-T34A cells 
began to apoptose through a caspase-2- and caspase-9-dependent pathway that was fur-
ther enhanced by the addition of other chemo- and radiotherapeutic modalities. Together 
our findings suggest a novel microenvironmental function for Survivin in the control of 
cancer aggressiveness and spread, and should result in the genesis of additional cancer 
treatment modalities. 
Keywords: tumor microenvironment, survivin, apoptosis, metastasis 
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Introduction 
The complexity and heterogeneity of the tumor microenvironment (Tredan, 
Galmarini et al. 2007) is believed to have an important function in the development, 
growth, metastasis, and therapy resistance of many cancers (Ohtani 1998). The tumor is 
not merely a single genotype-containing clonal mass but a community of heterogeneous 
cancer cells and stromal cells embedded in an extracellular matrix and nourished by vas-
cular and fibroblast cell networks (Aznavoorian, Stracke et al. 1990). 
The multifunctional protein Survivin controls diverse cellular functions, including 
surveillance checkpoints, suppression of cell death, the regulation of mitosis, and the ad-
aptation to unfavorable environments (Li, Ambrosini et al. 1998, Altieri 2003, Altieri 
2006). The suppression of cell death activities and baculovirus inhibitor of apoptosis pro-
tein (IAP) repeat (BIR) domain characterizes Survivin as a member of the IAP family 
(Ambrosini, Adida et al. 1997). However, Survivin's lack of a C-terminal RING finger 
domain and a caspase recruitment domain (Deveraux and Reed 1999) makes it structural-
ly unique among the mammalian IAPs. The multifaceted functionality of Survivin is still 
being intensely scrutinized, although it appears that protein compartmentalization may be 
important. Survivin was recently shown to colocalize in the mitochondria, where it abol-
ishes tumor cell apoptosis and promotes tumorigenesis in immunocompromized animals 
(Dohi, Beltrami et al. 2004). Survivin may therefore possess a function in apoptosis simi-
lar to the pro-apoptotic Bcl-2 family proteins. Furthermore, Survivin has been also found 
in the nucleus and cytosol where the implication is that it has functions in mitosis regula-
tion and apoptosis inhibition, respectively (Fortugno, Wall et al. 2002). Survivin is 
expressed in most common human cancers and although present during embryonic and 
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fetal development, it is undetectable in a variety of adult tissues (Adida, Crotty et al. 
1998) and for this reason it is currently recognized as an important anticancer target 
(Fukuda and Pelus 2006). For this purpose, multiple strategies have been successfully 
investigated, including the molecular antagonists such as antisense oligos, RNA inhibi-
tion, dominant-negative mutants, Survivin-specific cytolytic T cells, a non-
phosphorylatable Survivin mutant Thr34 → Ala (T34A), and most recently, binding in-
terface mimetics (Olie, Simoes-Wust et al. 2000, Andersen, Pedersen et al. 2001, 
Grossman, Kim et al. 2001, Kanwar, Shen et al. 2001, Mesri, Wall et al. 2001, Wall, 
O'Connor et al. 2003, Plescia, Salz et al. 2005). 
In the present study, we investigate whether extracellular compartmentalization of 
Survivin participates in the cytoprotection, tumorigenesis, and enhanced metastasis en-
countered in the tumor microenvironment. We have identified a novel pool of Survivin, 
localized extracellularly that is readily taken up by cancer cells but not by normal stromal 
cells. Furthermore, cancer cells that absorb Survivin show enhanced growth patterns and 
are more resistant to genotoxic stress than controls containing only endogenous levels of 
Survivin. Further investigations to define uptake-induced phenotypes of the apoptosis 
inducing non-phosphorylatable Survivin-mutant (T34A) have shown a caspase-dependent 
enhancement of chemotherapy-induced cell death, in vitro. 
 
Materials and Methods 
Cell Lines and Cultures 
Cervical carcinoma (HeLa and HeLa-S), osteosarcoma (U2OS and SaOS2), pan-
creatic carcinoma (Panc1, Capan1, and Capan2), prostate carcinoma (PC3, DU-145, and 
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RWPE-2), and breast carcinoma (MCF-7, HCC 1806) cell lines were obtained from the 
American Type Culture Collection (ATCC) as were the human normal prostate stromal 
cells (PrSC). The acute monocytic leukaemia cell lines (MOLM-14 and MV4-11) were a 
kind gift from CS Chen (Loma Linda University). Normal prostate epithelial cells (PrEC) 
were obtained from Clonetics-BioWhittaker (Walkersville, MD, USA) and cultured in 
PrEMB medium (Clonetics-BioWhittaker). The normal human bone marrow stromal 
(HBMS) cells were a generous gift of Kimberly Payne (Loma Linda University). Stromal 
cells were isolated and propagated as previously described (Hao, Shah et al. 1995) from 
adult human bone marrow that was purchased from Poietics Cell Systems (Lonza Walk-
ersville Inc., Gaithersburg, MD, USA). Human peripheral blood mononuclear cells were 
isolated from a peripheral blood draw using Ficoll-Hypaque (GE Healthcare Bio-
Sciences Corp., Piscataway, NJ, USA) as has been previously described (Wang, Azzo et 
al. 1984). The use of all human tissues was reviewed and approved by the institutional 
review board at Loma Linda University with informed written consent obtained from 
each subject. Cells were maintained as defined in DMEM, McCoy's, RPMI, or IMEM 
(ATCC) supplemented with 100 U of penicillin, 100 μg ml−1 streptomycin, 300 μg of l-
glutamine, and 10–20% heat inactivated fetal bovine serum (FBS; ATCC). Cells were 
grown at 37°C in a humidified atmosphere of 95% air, 5% CO2 until 60% confluent and 
supernatants were removed. New medium was given and cells were grown to 90% con-
fluent, after which supernatants were collected, centrifuged for 10 min at 2500 r.p.m., 
and stored at −20°C until use. 
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Expression Plasmid and Generation of Stable Cell Lines 
The detailed procedure for cloning and propagation has been described previously 
(Ogawa, Ishiguro et al. 2002, Shi, Sawada et al. 2003). In brief, recombinant retroviruses 
expressing a bicistronic messenger RNA containing open-reading frames of Flag-HA 
(hemagglutinin)-tagged human Survivin or human T34A-Survivin and interleukin-2 re-
ceptor (IL-2R)-α were constructed and transduced into HeLa cells. The infected HeLa 
cells were sorted by anti-IL-2R monoclonal antibody (mAb) conjugated with magnetic 
beads, and the resulting Flag-HA-Survivin or Flag-HA-T34A-Survivin stable cell lines 
propagated as suspension cultures. The expression level of both the wild-type (WT) and 
mutant (T34A) Survivin was evaluated by western analysis and immunohistochemistry 
with anti-Flag and HA antibodies (Santa Cruz Biotechnology Inc., Santa Cruz, CA, 
USA). 
 
Survivin Depletion 
Conditioned medium (CM) from stable Survivin-expressing HeLa cells contains 
Survivin that has a Flag-HA tag as well as normal endogenous Survivin. To deplete the 
medium of Survivin, we added anti-Flag beads (20 μl/ml) to the medium and rotated 
overnight at 4°C. The medium was centrifuged at 2000 r.p.m. for 5 min to pellet the 
beads. The supernatant was collected and 100 μl set aside for analysis by ELISA. The 
pelleted beads were collected and put in at −20°C. The remaining medium was treated 
with anti-HA beads (20 μl/ml) in a similar manner to remove the remaining tagged Sur-
vivin. To deplete the endogenous Survivin, we added anti-Survivin polyclonal antibodies 
(10 μl/ml) and anti-rabbit beads (20 μl/ml) to the medium and rotated overnight at 4°C. 
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The 100 μl aliquots at each stage were used in an ELISA to confirm the depletion. The 
beads collected at each step were incubated in 40 μl sample loading buffer at 100°C for 4
min, then centrifuged at 2000 r.p.m. for 5 min. A western blot of the supernatant was 
used to further confirm depletion. 
 
Quantitation of Survivin from CM  
(Cell Culture Supernatants) 
Conditioned medium was collected from 90% confluent cell cultures with cell vi-
ability assessed by Trypan blue exclusion (Sigma-Aldrich, St Louis, MO, USA). One-
half of the medium was concentrated 4 × using a speed-vac (Savant OligoPrep 120) after 
which unconcentrated and concentrated samples were assayed for the presence of Sur-
vivin using the Quantikine Human Survivin immunoassay kit (R&D Systems Inc., 
Minneapolis, MN, USA), according to the manufacturer's instructions. To quantify repre-
sentative Survivin protein from cultures experiencing cell death, we grew HeLa cells to 
90% confluence as previously described after which 0.1, 1.0, and 10% of these cells were 
lysed and their protein used to ‘spike' control medium for ELISA. 
 
Immunofluorescence Localization of Protein 
Cells were plated in six-well plates on 22 × 22 mm coverslips and cultured with 2
ml of control or CM (Surv-WT-CM, Surv-T34A-CM). Wells were washed with PBS and 
fixed in 4% paraformaldehyde for 30 min at room temperature. Cells were permeabilized 
with 0.5% NP-40 in PBS for 15 min, blocked with 5% FBS in 0.01% NP-40/PBS for 30
min, incubated for 1 h with 1 : 500 dilution of anti-Flag/HA mAbs (Sigma-Aldrich). 
Cells were incubated with Alexa Fluor-555-conjugated rabbit anti-mouse IgG secondary 
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antibody (Invitrogen/Molecular Probes, Eugene, OR, USA), mounted with Vectashield 
mounting media containing DAPI (Vector Laboratories, Burlingame, CA, USA) and ob-
served (× 1000) under an Olympus BX50 fluorescent microscope (Olympus America 
Inc., Center Valley, PA, USA). 
 
Image Acquisition Using Laser-scanning Confocal Microscopy 
Sampled sections were imaged and analyzed with an Olympus FV 1000 laser-
scanning confocal imaging system mounted onto an Olympus IX81 microscope (Olym-
pus America Inc.). Microscopic data were acquired with a 60× oil immersion objective 
lens. In each section, confocal stack images from representative fields of view per section 
were captured. The distance between each focal plane was 1 μm. 
 
Protein Expression and Purification 
Recombinant WT or mutated (T34A) proteins were expressed as glutathione-S-
transferase (GST) fusion proteins in the Escherichia coli BL21-CodonPlus-RIL (Strata-
gene, La Jolla, CA, USA) strain with induction in 0.2 mm isopropyl-β-d-
thiogalactopyranoside (IPTG) for 5 hrs. at 30°C. BIRC5 (Survivin) was purchased from 
Abnova (Walnut, CA, USA). The cells were harvested by centrifugation at 6000 g for 20
min, suspended in 50 mm Tris (pH 7.4), 150 mm NaCl, 5 mm MgCl2, and 1 mm dithio-
threitol, and lysed by sonication. After centrifugation at 15 000 g for 30 min, we mixed 
the soluble fractions with glutathione-agarose beads (Sigma-Aldrich) and incubated for 1
h at 4°C. After centrifugation at 1000 g for 1 min, we washed beads containing proteins 
three times in 50 mm Tris (pH 7.4), 500 mm NaCl, 5 mm MgCl2, and 1 mm dithio-
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threitol and further purified by chromatography over Econo-Column (Bio-Rad, Hercules, 
CA, USA) after overnight thrombin (Sigma-Aldrich) treatment to release the GST frame. 
The protein concentrations were measured using a protein assay reagent (Pierce, Rock-
ford, IL, USA) with BSA as standard. Recombinant transferrin protein was purchased 
from Sigma-Aldrich. The expression vector PRSET-CTB contained a gene encoding the 
entire cholera toxin B subunit (CTB) protein (11.6 kDa), driven by the T7 bacteriophage 
promoter region and containing an oligonucleotide encoding 6 histidines immediately 
upstream of the CTB gene for nickel column isolation of the recombinant protein was 
built as described (Carter, Yu et al. 2006). Briefly, CTB protein synthesis was stimulated 
by addition of 90 mg IPTG to the bacterial culture for 6 h at 37°C. Cells were harvested 
by centrifugation with the pellet resuspended in 10 mm HEPES buffer (pH 7.5), contain-
ing 100 mm imidazole. The cells were disrupted by sonication at 3 × 10 s bursts at 10 W, 
with a Sonic 60 Dismembrator. Cholera toxin B subunit protein was isolated from the 
homogenate by a Maxwell Model 16 robotic protein purification system (Promega Inc., 
Madison, WI, USA), according to the protein isolation protocol provided by the manufac-
turer. Purity of the isolated CTB protein was determined by electrophoretic mobility 
measurement in a 12% polyacrylamide gel. Imidazole was removed from the protein 
mixture by dialysis of the preparation against 10 mm HEPES buffer (pH 7.5), for 4 hrs. at 
4°C. 
 
IR-Dye Labeling of Recombinant Proteins and In-cell  
Western Blotting 
IR-Dye labeling was performed according to the manufacturer's instructions (LI-
COR Biosciences, Lincoln, NE, USA). Briefly, 100 μg of transferrin, CTB, and 10 μg of 
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BIRC5 was labeled at 20°C for 2 hrs.. Labeled protein was column purified as described 
by the manufacturer. HeLa cells (5 × 103 per well) were plated in 96-well plates. After 
overnight culture, we added labeled BIRC5, transferrin, and CTB proteins at doses of 1
μg, 0.01 μg, and 0.001 μg in duplicate wells. After overnight culture, we washed cells 
vigorously 3–4 times with PBS to remove all remaining unattached recombinant protein. 
Cells were fixed with 4% paraformaldehyde and an in-cell western blot was performed 
using Survivin polyclonal antibody (Novus, Littleton, CO, USA) according to the manu-
facturer's instructions. The 96-well plate was then scanned immediately in both 700 and 
800 nm channels. Relative fluorescent intensity was determined using our Odyssey Infra-
red Imaging system and software. 
 
Colony Formation Assay 
The cells were plated in 10 cm dishes at a density of 100 000 cells per well, incu-
bated at 37°C overnight, and then were treated with the indicated control, Surv-WT-CM, 
and Surv-T34A-CM for up to 48 hrs.. The cells were fixed with methanol and stained 
with crystal violet. 
 
Cell Cycle Synchronization 
HeLa-S cells were G1-arrested for 16 hrs. using mimosine as previously de-
scribed (Li, Ackermann et al. 1999). Cells were then released and treated with either 
Surv-WT-CM or control medium and then harvested after 0, 3, 6, 9, and 12 hrs.. Cells 
were analyzed for DNA content by propidium iodide staining and flow cytometry (Bec-
ton Dickinson, San Jose, CA, USA). 
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Apoptosis and Cell Cycle Analysis 
Subconfluent cultures of the various cell lines were incubated with vehicle 
(DMSO), taxol (4 μm; Sigma-Aldrich), 5-flurouracil (5-FU, 200 nm; Sigma-Aldrich), 
adriamycin (Ad, 100 nm, Sigma-Aldrich), cisplatin (CDPD, 2 μm; Sigma-Aldrich) or ex-
posed to ultraviolet B (UVB) irradiation at 50 J m−2 with or without the presence of WT-
CM, T34A-CM, or control for 24 and 48 hrs. at 37°C. Cells were harvested, prepared, 
and analyzed for DNA content as described previously (Li, Ackermann et al. 1999). DNA 
content was analyzed using a Becton Dickinson FACScan flow cytometer (Becton Dick-
inson). The distribution of cells in the different phases of the cell cycle was analyzed 
from DNA histograms using BD CellQuest software (Becton Dickinson). 
 
AlamarBlue (AB) Assay for Cell Proliferation 
Initial experiments were carried out to follow per cent AB (%AB) reduction over 
time. The aim was to determine the optimal seeding density and culture period. HeLa 
cells, trypsinized from subconfluent cultures as described earlier, were suspended in cul-
ture medium containing 1% FBS, T34A-CM, and WT-CM and then seeded into duplicate 
wells of a 96-well plate (200 ml well) at concentrations of 1.5 × 104–1 × 106 cells per ml 
at standard culture conditions of 5% CO2 in air at 37°C. After an initial 4 hrs. period to 
allow for cell attachment, we added AB (BioSource, Camarillo, CA, USA) directly into 
culture medium at a final concentration of 10% and the plate was returned to the incuba-
tor. Optical density of the plate was measured at 540 and 630 nm with a standard 
spectrophotometer at 1, 3, 6, 12, 24, 48, and 72 hrs. after adding AB. Because the culture 
medium was not changed during this period, the calculated %AB reduction is a cumula-
32 
tive value. As a negative control, AB was added to medium without cells. 
 
Caspase Activity Assay 
Caspase activity was quantitated using the ApoAlert Caspase Assay Plates (Clon-
tech, Mountain View, CA, USA). Fluorogenic substrates specific for caspase-3, caspase-
8, caspase-9, and caspase-2 were immobilized in the wells of a 96-well plate. Fluores-
cence was detected using a standard fluorescence plate reader in the presence or absence 
of the specific caspase inhibitor. 
 
Western Blot Analysis 
Cells were solubilized, proteins (20–40 μg) separated using 12% Bis-Tris poly-
acrylamide gels, proteins transferred onto polyvinylidene difluoride membranes 
(Millipore, Temecula, CA, USA) and probed using the following antibodies: mouse 
monoclonal anti-Flag and anti-HA (Sigma-Aldrich), rabbit polyclonal anti-Survivin 
(Novus), rabbit polyclonal antibodies to caspase-7, caspase-9, PARP and GAPDH (Cell 
Signaling Technologies, Beverly, MA, USA), mouse mAbs to β-actin (Abcam, Cam-
bridge, MA, USA), and mouse mAb to caspase-2 (Cell Signaling Technologies). 
Secondary antibodies (IR-Dye-conjugated) were goat anti-rabbit and goat anti-mouse 
immunoglobulin (LI-COR Biosciences). Immunoreactive bands were detected using the 
Odyssey imaging system (LI-COR Biosciences) and quantified using ImageQuant soft-
ware (Amersham Biosciences, Piscataway, NJ, USA). Protein quantifications presented 
in this report were normalized with respect to β-actin or GAPDH. 
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Mitochondrial Permeability Detection 
Mitochondrial depolarization is detected by a unique fluorescent cationic dye 
5,5′,6,6′-tetrachloro-1,1′,3,3′-tetraethyl-benzamidazolocarbocyanin iodide, also known as 
JC-1 (Invitrogen/Molecular Probes). Cells were collected and washed with PBS and pre-
pared for the analysis according to the manufacturer's instructions. 
 
Collagen Cell Invasion Assay 
Cellular invasion was studied using the QCM 96-well Fluorometric Collagen-
based Cell Invasion Assay from Chemicon International (Millipore) according to the 
manufacturer's instructions. Briefly, single-cell suspensions were obtained by trypsiniza-
tion of monolayer cultures of HeLa cells. Cell counts and viability were performed using 
Trypan blue staining after overnight serum starvation. Cells (25 000 cells per well) were 
plated on 8 μm pore size collagen-coated inserts in 96-well plates. Cells were grown for 
24 h with control media, Surv-WT-CM, Surv-T34A-CM, medium that was depleted of 
Survivin introduced into the lower chamber or medium taken from cells treated with cy-
tochalasin D, a known inhibitor of exocytosis that works by specifically disrupting 
microfilaments. Survivin was depleted using one round of anti-Flag antibody, one round 
of anti-HA antibody, and either 1 (depleted 1 × ) or 3 (depleted 3 × ) rounds of anti-
Survivin antibody. A control, termed blank, was performed using only cell detachment 
buffer, lysis buffer, and CyQuant dye without cells. Invasive cells, migrating through the 
polymerized collagen layer, were dissociated using cell detachment buffer as described 
by the manufacturer and lysed. Fluorescence emission (CyQuant GR dye) was assessed 
by a fluorescent plate reader (Molecular Dynamics, Sunnyvale, CA, USA). 
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Statistical Analysis 
Statistical analysis was performed using a two-way analysis of variance with the 
aid of JMP statistical software (Cary, NC, USA). A paired t-test was used for group anal-
ysis. Caspase-2, caspase-7, and caspase-9 densitometric analysis was conducted using our 
AlphaImager EC (Alpha Innotech, San Leandro, CA, USA). Density of individual bands 
was divided by GAPDH as the internal control with each timed sample then divided by 
the particular time period control. As 6 hrs. staurosporine did not have a 6 hrs. control, 
these were also controlled against the 24 hrs. control samples. 
 
Results 
Stable Expression of Wild-Type and Mutant T34A Survivin  
leads to Survivin Secretion 
We and others (Bokarewa, Lindblad et al. 2005, Mera, Magnusson et al. 2008) re-
cently found and reported a form of Survivin that is found in the extracellular space. 
Using a commercially available Survivin ELISA, we were able to quantitate picogram 
amounts of Survivin from CM taken from tumor cell lines representative of the most 
common cancer types, including pancreatic, breast, prostate, cervical, sarcoma, and acute 
monocytic leukaemia (Table 1). To determine whether this extracellular form of Survivin 
was merely released as a result of an excretory process, the result of cellular necrosis, or 
whether its function was secretory and would be important in the context of the tumor 
microenvironment, that is absorbed into cells, we needed to construct a form of Survivin 
different from the endogenous form. We therefore generated stable HeLa cells expressing 
human Survivin (Surv-WT) tagged with both the Flag and HA epitopes at their N termi-
nus. Immunohistochemistry (Figure 4A) as well as western blotting (Figure 5) using 
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antibodies to either HA or Flag revealed the Survivin fusion protein. The Surv-T34A mu-
tant has shown promise in initiating the mitochondrial apoptotic pathway (Mesri, Wall et 
al. 2001) and if also detected extracellularly could provide a form of Survivin suitable for 
therapeutic manipulation. We therefore generated stable HeLa cells expressing the non-
phosphorylatable Surv-T34A mutant. Immunohistochemistry (Figure 4B) and western 
blotting (Figure 5) revealed the HA-Flag-Survivin fusion protein. The generation of this 
cell line took many attempts, and many months, as the Surv-T34A mutant was very toxic 
to the HeLa cells. Further analysis of allowing mutations has not yet taken place. 
Conditioned medium taken from these stable Surv-WT or Surv-T34A HeLa cells 
showed picogram amounts of Survivin by ELISA (Table 1). Interestingly, it was quite 
apparent that accumulation of the T34A mutant Survivin and that from the parent HeLa-S 
cells was limited in comparison to that which accumulated in the medium from the Surv-
WT cells (Table 1). To evaluate this disparity, we evaluated Survivin protein concentra-
tion, determined using ELISA, on a per cell basis. Dividing the measured amount of 
protein by the number of cells that were present provides evidence that the Surv-WT cells 
truly do release more protein into the CM than does the control cells or the Surv-T34A-
producing cells (Figure 6A). AB staining was next used to determine if this phenomenon 
was the result of cellular division. As recorded in Figure 6B, AB reduction in the Surv-
WT HeLa-S cells represented a state of enhanced cellular growth when compared to the 
controls or the Surv-T34A cells. Surv-T34A HeLa-S cell proliferation is significantly re-
duced when compared to the Surv-WT and control HeLa-S cells. Also, there was no 
significant difference in the level of cell proliferation recorded in the Surv-T34A-
expressing cells when compared to medium where no cells were being grown (Figure 6B, 
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blank), indicating that Surv-T34A may reduce the level of released Survivin as a result of 
its stifling cell growth. We next evaluated the functional importance of this extracellular 
Survivin protein. HeLa cells were incubated for 24 h in CM taken from control, Surv-
WT, or Surv-T34A stable cells. Immunohistochemical staining (Figure 7A) and western 
blotting (Figure 7B), using antibodies to HA, showed that the Survivin fusion proteins are 
readily taken up. A retarded band of approximately 18 kDa appeared in the HeLa-S ly-
sates of cells incubated in WT- and T34A-CM representing the Flag-HA-Survivin fusion 
protein (Figure 7B), which was not observed in control conditioned medium grown HeLa 
cells. Interestingly, the cells that were incubated in Surv-T34A-CM took on a shrunken 
appearance and were fewer in number compared to the control medium-incubated cells 
(Figure 7A) whereas the Surv-WT, CM-incubated cells appeared to be healthier and in 
greater numbers. Phase-contrast microscopy allowed enhanced visualization of this 
shrunken phenotype and the initiation of apoptotic bodies in these T34A-CM-treated 
cells. To ensure that the ability of cells to uptake Survivin from the CM was a general 
occurrence and not specific for the HeLa cells, we also incubated Capan1, Capan2, MCF-
7, Panc1, PC3, SaOS2, U2OS, HCC, and HBMS cells in HA-Flag-survivin-containing 
CM. All cancer cells were able to take up the Survivin from the medium whereas the 
normal HBMS cells did not (Figure 8A). Western blots (Figure 8B) from these cells con-
firmed the uptake results as every cell type except HBMS, when incubated in Surv-WT-
CM, expressed 18 kDa band representing the Flag-HA-Survivin fusion  
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Figure 4.  HeLa cells express the Flag-HA-Survivin fusion protein.  Wild type Survivin 
(A) and T34A mutant Survivin (B) transformed HeLa cells were selected four times us-
ing magnetic beads conjugated to the IL-2 Receptor antibody.  Cells were fixed and 
stained using HA and Flag antibodies as described in the methods and materials.  Magni-
fication x1000. 
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Figure 5. HeLa cells that expressed the stable Flag-HA-Survivin fusion protein were 
harvested and analyzed by Western blotting with antibodies against Survivin, HA, and 
Flag in order to support the immunohistochemical findings.  As blots were often first 
probed with antibodies to Survivin and then with antibodies to Flag or HA, a doublet 
band (indicated by arrows) occurs with Survivin being 16.5 KDa and the Flag/HA retard-
ing the band to ~18 KDa.  A third band, labeled * often appears after probing with the 
antibodies to Flag and HA whose identity is yet unknown to us.  GAPDH blotting was 
used as loading control.  Molecular-weight markers in kilodaltons (KDa) are shown on 
the left. Supl. Figure 1C 
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Table 1. Quantitative analysis of Survivin in conditioned medium of cancer cell lines by ELISA 
 
Collagen cell invasion assay
Cellular invasion was studied using the QCM 96-well Fluorometric
Collagen-based Cell Invasion Assay from Chemicon International
(Millipore) according to the manufacturer’s instructions. Briefly,
single-cell suspensions were obtained by trypsinisation of mono-
layer cultures of HeLa cells. Cell counts and viability were
performed using Trypan blue staining after overnight serum
starvation. Cells (25000 cells per well) were plated on 8mm pore
size collagen-coated inserts in 96-well plates. Cells were grown for
24h with control media, Surv-WT-CM, Surv-T34A-CM, medium
that was depleted of survivin introduced into the lower chamber or
medium taken from cells treated with cytochalasin D, a known
inhibitor of exocytosis that works by specifically disrupting
microfilaments. Survivin was depleted using one round of anti-
Flag antibody, one round of anti-HA antibody, and either 1
(depleted 1 ) or 3 (depleted 3 ) rounds of anti-survivin
antibody. A control, termed blank, was performed using only cell
detachment buffer, lysis buffer, and CyQuant dye without cells.
Invasive cells, migrating through the polymerised collagen layer,
were dissociated using cell detachment buffer as described by the
manufacturer and lysed. Fluorescence emission (CyQuant GR dye)
was assessed by a fluorescent plate reader (Molecular Dynamics,
Sunnyvale, CA, USA).
Statistical analysis
Statistical analysis was performed using a two-way analysis of
variance with the aid of JMP statistical software (Cary, NC, USA).
A paired t-test was used for group analysis. Caspase-2, caspase-7,
and caspase-9 densitometric analysis was conducted using our
AlphaImager EC (Alpha Innotech, San Leandro, CA, USA). Density
of individual bands was divided by GAPDH as the internal control
with each timed sample then divided by the particular time period
control. As 6h staurosporine did not have a 6h control, these were
also controlled against the 24h control samples.
RESULTS
Stable expression of wild-type and mutant T34A survivin
leads to survivin secret ion
We and others (Bokarewa et al, 2005; Mera et al, 2008) recently
found and reported a form of survivin that is found in the
extracellular space. Using a commercially available survivin ELISA,
we were able to quantitate picogram amounts of survivin from CM
taken from tumour cell lines representative of the most common
cancer types, including pancreatic, breast, prostate, cervical,
sarcoma, and acute monocytic leukaemia (Table 1). To determine
whether this extracellular form of survivin was merely released as a
result of an excretory process, the result of cellular necrosis, or
whether its function was secretory and would be important in the
context of the tumour microenvironment, that is absorbed into
cells, we needed to construct a form of survivin different from the
endogenous form. We therefore generated stable HeLa cells
expressing human survivin (Surv-WT) tagged with both the Flag
and HA epitopes at their N terminus. Immunohistochemistry
(Supplementary Figure 1A) as well as western blotting (Supple-
mentary Figure 1C) using antibodies to either HA or Flag revealed
the survivin fusion protein.
The Surv-T34A mutant has shown promise in initiating the
mitochondrial apoptotic pathway (Mesri et al, 2001) and if also
detected extracellularly could provide a form of survivin suitable
for therapeutic manipulation. We therefore generated stable HeLa
cells expressing the non-phosphorylatable Surv-T34A mutant.
Immunohistochemistry (Supplementary Figure 1B) and western
blotting (Supplementary Figure 1C) revealed the HA-Flag-survivin
fusion protein. The generation of this cell line took many attempts,
and many months, as the Surv-T34A mutant was very toxic to the
HeLa cells. Further analysis of allowing mutations has not yet
taken place.
Conditioned medium taken from these stable Surv-WT or
Surv-T34A HeLa cells showed picogram amounts of survivin by
ELISA (Table 1). Interestingly, it was quite apparent that
Table 1 Quantitative analysis of survivin in conditioned medium of cancer cell lines by ELISA
Cell t ype Cell lines pg ml 1 s.e.m. Concent rated (pg ml 1) s.e.m.
Cervical cancer HeLa ND — 330.4 11.4
HeLa-S 94.0 42.1 746.1 1.4
HeLa-S-Surv-WT 619.0 24.3 1158.3 32.1
HeLa-S-Surv-T34A 35.2 0.01 81.9 0.01
HeLa-S-survivin
Antibody depletion
ND — ND —
Pancreatic cancer Capan1 246.9 13.6 1204.7 14.3
Capan2 ND — 26.1 8.6
Panc1 20.4 42.9 174.7 47.1
Prostate cancer PC3 73.3 32.9 888.3 5.0
Du-145 136.9 37.4 771.9 24.0
RWPE-2 29.0 16.0 337.6 7.0
Osteosarcoma U2OS ND — 210.4 14.3
SaOS2 405.4 50.0 858.3 50.7
Breast cancer MCF-7 63.0 2.0 175.4 1.7
HCC TN ND — 19.0 1.4
Acute monocytic leukaemia MOLM-14 ND — 273.3 23.3
MV4-11 ND — 347.6 15.9
Human bone marrow stroma HBMS (normal) ND — ND —
Prostate epithelial cells PrECs (normal) ND — ND —
Prostate stromal cells PrSCs (normal) ND — ND —
Peripheral blood mononuclear cells PBMCs (normal) ND — ND —
Media control Media control ND — ND —
Spiked media control 0.1% lysed cells ND — 3.2 0.7
1.0% lysed cells 77.6 1.1 121.9 2.0
10% lysed cells 259.7 8.3 596.1 37.0
ND ¼none detected.
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Figure 6. Comparison of extracellular Survivin protein concentrations and cellular me-
tabolism of the cervical carcinoma HeLa cells that were stable transfectants of the 
Survivin-WT (Surv-WT) or mutant survivin T34A (Surv-T34A). (A) ELISA-defined 
Survivin concentrations were measured in medium taken from the different stable HeLa 
cells lines as described in Materials and methods section. For each cell line, the Survivin 
protein concentration was divided by the number of cells defined by Trypan blue exclu-
sion at the time of medium collection. (B) Alamar Blue fluorimetry was conducted in the 
same three cell lines to determine if the stable expression of Survivin or its mutant would 
affect the cell growth and metabolism. Measurements were also conducted in medium 
containing no cells (blank), which would represent no growth or metabolism. Data are the 
mean±s.e. of three independent experiments (*P<0.001) as compared to the control. 
  
accumulation of the T34A mutant survivin and that from theparent
HeLa-S cells was limited in comparison to that which accumulated
in the medium from the Surv-WT cells (Table 1). To evaluate this
disparity, we evaluated survivin protein concentration, determined
using ELISA, on a per cell basis. Dividing the measured amount of
protein by the number of cells that were present provides evidence
that the Surv-WT cells truly do release more protein into the CM
than does the control cells or the Surv-T34A-producing cells
(Figure 1A). AB staining was next used to determine if this
phenomenon was the result of cellular division. As recorded in
Figure 1B, AB reduction in the Surv-WT HeLa-Scells represented a
state of enhanced cellular growth when compared to the controls or
the Surv-T34A cells. Surv-T34A HeLa-S cell proliferation is
significantly reduced when compared to the Surv-WT and control
HeLa-Scells. Also, there was no significant difference in the level of
cell proliferation recorded in the Surv-T34A-expressing cells when
compared to medium where no cells were being grown (Figure 1B,
blank), indicating that Surv-T34A may reduce the level of released
survivin as a result of its stifling cell growth.
We next evaluated the functional importance of this extra-
cellular survivin protein. HeLa cells were incubated for 24h in
CM taken from control, Surv-WT, or Surv-T34A stable cells.
Immunohistochemical staining (Figure 2A) and western blotting
(Figure 2B), using antibodies to HA, showed that the survivin
fusion proteins are readily taken up. A retarded band of
approximately 18kDa appeared in the HeLa-S lysates of cells
incubated in WT- and T34A-CM representing the Flag-HA-
survivin fusion protein (Figure 2B), which was not observed in
control conditioned medium grown HeLa cells. Interestingly, the
cells that were incubated in Surv-T34A-CM took on a shrunken
appearance and were fewer in number compared to the control
medium-incubated cells (Figure 2A) whereas the Surv-WT, CM-
incubated cells appeared to be healthier and in greater numbers.
Phase-contrast microscopy allowed enhanced visualisation of this
shrunken phenotype and the initiation of apoptotic bodies in these
T34A-CM-treated cells. To ensure that the ability of cells to uptake
survivin from theCM was a general occurrence and not specific for
the HeLa cells, we also incubated Capan1, Capan2, MCF-7, Panc1,
PC3, SaOS2, U2OS, HCC, and HBMS cells in HA-Flag-survivin-
containing CM. All cancer cells were able to take up the survivin
from the medium whereas the normal HBMS cells did not
(Figure 3A). Western blots (Figure 3B) from these cells confirmed
the uptake results as every cell type except HBMS, when incubated
in Surv-WT-CM, expressed 18kDa band representing theFlag-HA-
survivin fusion protein. Previous work performed on neutrophils
showed survivin not entering the cells but binding to the surface
(Mera et al, 2008). It was therefore necessary to perform confocal
microscopy to ensure survivin’s relocalisation within the cells.
Taking photographs at 1mm increments throughout the cell
(shown schematically in Figure 4K) indicated that in these HeLa
cells, survivin was not only inside the cells but also relocalised
within the cytoplasm and to the nucleus (Figure 4).
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Figure 1 Comparison of extracellular survivin protein concentrations and cellular metabolism of the cervical carcinoma HeLa cells that were stable
transfectants of the survivin-WT (Surv-WT) or mutant survivin T34A (Surv-T34A). (A) ELISA-defined survivin concentrations were measured in medium
taken from the different st ble HeLa cells lines as described in Materials and methods section. For each cell lin , the survivin protein concentration was
divided by the number of cells defined by Trypan blue exclusion at the time of medium collection. (B) Alamar Blue fluorimetry was conducted in the same
three cell lines to determine if the stable expression of survivin or its mutant would affect the cell growth and metabolism. Measurements were also
conducted in medium containing no cells (blank), which would represent no growth or metabolism. Data are the mean± s.e. of three independent
experiments (*Po 0.001) as compared to the control.
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protein. Previous work performed on neutrophils showed Survivin not entering the cells 
but binding to the surface (Mera, Magnusson et al. 2008). It was therefore necessary to 
perform confocal microscopy to ensure Survivin's relocalization within the cells. Taking 
photographs at 1 μm increments throughout the cell (shown schematically in Figure 10K) 
indicated that in these HeLa cells, Survivin was not only inside the cells but also relocal-
ized within the cytoplasm and to the nucleus (Figure 10). 
 
Relationship Between Survivin Absorption, Surv-T34A-induced  
Apoptosis, and Surv-WT-induced Cell Cycle Progression 
Consistent with the data presented in Figure 7A, HeLa cells grown in CM taken 
from stable Surv-T34A cells experienced enhanced numbers of hypodiploid cells, that is, 
sub-G1 DNA content or apoptotic cells (Figure 11A, inset) by DNA content analysis and 
flow cytometry. Furthermore, Trypan blue exclusion and colony formation assay evalua-
tion of these same cells showed a time-dependent, marked reduction in live cell numbers 
and live cell colonies in the Surv-T34A-CM-grown HeLa cells compared with cells 
grown in control medium or the CM from the Surv-WT cells (Figures 11A and B and 
Figure 9). This cell number reduced even further after 48 h as shown by the live cell col-
onies in the Surv-T34A-CM-grown HeLa cells, a finding that is consistent with what has 
been recorded by our own group and others (Mesri, Wall et al. 2001, O'Connor, Wall et 
al. 2002, Wall, O'Connor et al. 2003, Ogura, Watanabe et al. 2008) that the dominant-
negative Survivin mutant T34A induces as caspase-dependent apoptosis. In contrast, 
Trypan blue exclusion and colony formation assay evaluation of Surv-WT-CM-grown 
cells showed a time-dependent, marked increase in live cell numbers (four times) and live 
cell colonies (approximately two times), in comparison with cells 
 42 
 
 
Figure 7. HeLa cells incubated in Surv-WT- or Surv-T34A-conditioned medium take up 
the Flag-HA-Survivin fusion protein. (A) HeLa cells were cultured with control-, Surv-
WT-, or Surv-T34A-conditioned medium for 24 hrs. Cells were fixed and stained with 
antibodies to HA, magnification × 1000. Insets are western blots taken from cell lysates 
of these cells probed with antibodies to HA. Phase-contrast panels show the T34A-
associated shrunken phenotype and early apoptotic bodies in comparison with the control 
or WT-treated cells. (B) Western blot analysis using antibodies to both Survivin and Flag 
shows the retarded ~18 kDa band of the Flag-HA-Survivin fusion protein. Control lysates 
only show the presence of the 16.5 kDa endogenous Survivin. Molecular weight markers 
in kilodaltons (kDa) are shown on the left. 
  
Relationship between survivin absor tion,
Surv-T34A-induced apoptosis, and Surv-WT-induced
cell-cycle progression
Consistent with the data present d in Figur 2A, H La cells grown
in CM taken from stable Surv-T34A cells experienced enhanced
numbers of hypodiploid cells, that is, sub-G1 DNA content or
apoptotic cells (Figure 5A, inset) by DNA content analysis and
flow cytometry. Furthermore, Trypan blue exclusion and colony
formation assay evaluation of these same cells showed a time-
dependent, marked reduction in live cell numbers and live cell
colonies in the Surv-T34A-CM-grown HeLa cells compared with
cells grown in control medium or the CM from the Surv-WT cells
(Figures 5A and B and Supplementary Figure 2). This cell number
reduced even further after 48h as shown by the live cell colonies in
the Surv-T34A-CM-grown HeLa cells, a finding that is consistent
with what has been recorded by our own group and others (Mesri
et al, 2001; O’Connor et al, 2002; Wall et al, 2003; Ogura et al, 2008)
that the dominant-negative survivin mutant T34A induces as
caspase-dependent apoptosis. In contrast, Trypan blue exclusion
and colony formation assay evaluation of Surv-WT-CM-grown cells
showed a time-dependent, marked increase in live cell numbers
(four times) and live cell colonies (approximat ly two times), in
comparison with cellsgrown in control medium or theCM from the
Surv-T34A cells (Figures 5A and B and Supplementary Figure 2).
To further evaluate the cell-cycle progression effects observed in
the Surv-WT-CM-grown cells, we mimosine synchronised HeLa
cells for 16h, which effectively arrested cells in the G0/G1 phase of
the cell cycle. Mimosine was then removed and the cells were
incubated in the absence or presence of Surv-WT-CM. Cells were
then harvested at 0, 3, 6, 9, and 12h time points following CM
addition and cells were analysed by DNA content analysis and flow
cytometry. In comparison with cells grown in control medium,
Surv-WT-CM-grown cellshad a 10–12% increase in S-phasegrowth
in cells harvested after 6h and a 10% increase in thenumber of cells
in G2/M by 12h (Figure 5C). These findings are consistent with
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Figure 2 HeLacells incubated in Surv-WT- or Surv-T34A-conditioned medium take up the Flag-HA-survivin fusion protein. (A ) HeLacellswere cultured
with control-, Surv-WT-, or Surv-T34A-conditioned medium for 24h. Cellswere fixed and stained with antibodies to HA, magnification 1000. Insets are
western blotstaken from cell lysatesof these cellsprobed with antibodies to HA. Phase-contrast panelsshow the T34A-associated shrunken phenotype and
early apoptotic bodies in comparison with the control or WT-treated cells. (B) Western blot analysis using antibodies to both survivin and Flag shows the
retarded B 18kDa band of the Flag-HA-survivin fusion protein. Control lysates only show the presenc of th 16.5kDa endogenous survivin. Molecular
weight markers in kilodaltons (kDa) are shown on the left.
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Figure 8. Cancer cells but not normal cells incubated in Surv-WT-conditioned medium 
take up the Flag-HA-Survivin fusion protein. (A) HeLa, Capan1, Capan2, MCF-7, Panc1, 
PC3, SaOS2, U2OS, HCC, and HBMS cells were cultured with control- or Surv-WT-
conditioned medium for 24 h. Cells were fixed and stained with antibodies to HA, magni-
fication × 1000. (B) Western blot analysis using antibodies to Survivin shows the 
retarded ~18 kDa band of the Flag-HA-Survivin fusion protein only in those lysates from 
the cells grown in conditioned medium. A third band, labeled*, often appears after prob-
ing with the antibodies Survivin whose identity is yet unknown to us. Molecular weight 
markers in kilodaltons (kDa) are shown on the left.  
those published indicating that survivin displays both anti-
apoptosis and promotion of mitosis in cancer cells (Li et al, 1998;
O’Connor et al, 2000; Chao et al, 2007). We are further encouraged
as our CM containing fusion proteins may prove useful for the
future study of survivin trafficking and T34A therapy in vivo.
Recombinant survivin protein lacks the function of
survivin-containing CM
Recombinant Surv-WT and Surv-T34A proteins were incapable of
affecting cell growth or apoptosis in our hands (Supplementary
Figure 3). It is uncertain whether bacterial-derived survivin
proteins are folded or modified properly for recognition by
cellular mechanisms of uptake. To test this hypothesis further, we
evaluated recombinant survivin (BIRC5), transferrin, and CTB
protein for cellular uptake using in-cell western assay methods
(Egorina et al, 2005). HeLa cells were incubated with increasing
concentrations of labelled recombinant protein, and the amount of
protein endocytosed after a 12h incubation w s measured as
shown in Figure 6. The amount of transferrin and CTB proteins
endocytosed increased in a dose-dependent manner. However,
survivin recombinant protein (BIRC5) at the same concentrations
was not endocytosed (Figure 6). Transferrin (Sandvig and van
Deurs, 1990) and CTB (Gizurarson et al, 1992; Frey et al, 1996;
B
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Figure 9.  Surv-T34A conditioned medium induces tumor cell apoptosis while Surv-WT 
conditioned medium promotes cell growth.  Cervical Carcinoma HeLa cells grown in the 
presence of either Surv-T34A or Surv-WT conditioned medium for 24 and 48 hours, 
were fixed with methanol and stained with crystal violet allowing visualization of the en-
hanced cellular proliferative effects of Surv-WT or the killing/growth repressive effects 
of Surv-T34A.  Plates shown are representative of one of two independent experiments 
with comparable results. 
 
  
24hr. 
 
 
 
 
 
 
48hr. 
Control Surv-WT Surv-T34A 
Supl. Figure 2 
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grown in control medium or the CM from the Surv-T34A cells (Figures 11A and B and 
Figure 9). 
To further evaluate the cell-cycle progression effects observed in the Surv-WT- 
CM-grown cells, we mimosine synchronized HeLa cells for 16 hrs., which effectively 
arrested cells in the G0/G1 phase of the cell cycle. Mimosine was then removed and the 
cells were incubated in the absence or presence of Surv-WT-CM. Cells were then har-
vested at 0, 3, 6, 9, and 12 hrs. time points following CM addition and cells were 
analyzed by DNA content analysis and flow cytometry. In comparison with cells grown 
in control medium, Surv-WT-CM-grown cells had a 10 – 12% increase in S-phase 
growth in cells harvested after 6 hrs. and a 10% increase in the number of cells in G2/M 
by 12 hrs. (Figure 11C). These findings are consistent with those published indicating 
that Survivin displays both anti- apoptosis and promotion of mitosis in cancer cells (Li, 
Ambrosini et al. 1998, O'Connor, Grossman et al. 2000, Chao, Su et al. 2007). We are 
further encouraged as our CM containing fusion proteins may prove useful for the future 
study of Survivin trafficking and T34A therapy in vivo. 
 
Recombinant Survivin Protein Lacks the Function  
of Survivin-containing CM 
Recombinant Surv-WT and Surv-T34A proteins were incapable of affecting cell 
growth or apoptosis in our hands (Figure 12). It is uncertain whether bacterial-derived 
Survivin proteins are folded or modified properly for recognition by cellular mechanisms 
of uptake. To test this hypothesis further, we evaluated recombinant Survivin, transferrin, 
and CTB proteins for cellular uptake using in-cell western assay  
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Figure 10. Confocal microscopy indicates that Survivin protein is taken up by cancer 
cells and is not merely binding to the cell surface. Cells were fixed and stained with anti-
bodies to HA, with pictures taken on a z-scale of 1 μm, magnification × 1000. (A–J) are 
z-scale pictures taken at 1μm intervals as represented in (K). 
  
Hansen et al, 2005) recombinant proteins were previously
described as subs rates for endocytic uptake and were used as
positive controls.
Character isation of tumour cell apoptosis induced by
Surv-T34A in vitro
We have shown in Figures 2A and 5A that incubating HeLa cells
with Surv-T34A-CM resulted in apoptosis. Cytofluorometric
quantification results showed that in comparison with control
media or Surv-WT-CM treatment, Surv-T34A treatments induced
robust results within 24 to 48h. Previous studies performed, using
an adenovirus-encoding T34A mutant, resulted in apoptosis that
was associated with the mitochondrial release of cytochrome c,
cleavage of caspase-9, and the processing of caspase-3 (Mesri et al,
2001). Further analysis of Surv-T34A-CM-induced apoptosis, using
a commercially available caspase activity assay, revealed that
Surv-T34A induced cleavage of caspase-9 and caspase-2 without
cleaving the substrates specific for caspase-3 or caspase-8
(Figure 7A). The antibiotic and protein kinase inhibitor, stauro-
sporine, was used as a positive control for caspase-3 activity. Surv-
WT-CM had no effect on the caspase activity under evaluation.
In addition, western blotting provided biochemical data that
supported studies recorded above for caspase-2, caspase-3, and
caspase-9. Using antibodies that were specific for the full-length,
non-cleaved forms of caspase-2, caspase-7, and caspase-9 and the
cl aved form of caspase-3 protein and staurosporine again as a
positive control, we found that Surv-T34A induced the parallel
time-dependent reduction in caspase-2, caspase-7, caspase-9, and
cleavage of the DNA repair protein PARP (Figure 7B). In all cases
the pan-caspase inhibitor Z-VAD-FMK was able to inhibit the
activity of Surv-T34A. In contrast, Surv-WT again had no obser-
vable effects on caspase cleavage when cells were treated with it
alone for up to 48h. Caspase-3 was robustly cleaved after 6h
of staurosporine treatment. However, this cleavage product was
absent after 24h indicating a complete cleavage and degradation of
caspase-3. Concomitant with this cleavage was the significant level
of PARP cleavage recorded at this 24h time point.
Loss of mitochondrial membrane potential after treatment
with Surv-T34A CM
Mitochondrial membrane potential (Dc m), a phenomenon readily
measured using the mitochondrial dye JC-1 and fluorescence-
activated cell sorting analysis (Salvioli et al, 1997), was evaluated
for the possibility that Surv-T34A was stimulating apoptosis by
inducing depolarisation within the mitochondria. Under normal
circumstances, JC-1 accumulates in the inner mitochondrial
membrane in which it oligomerises and fluoresces red. A reduction
in Dc m results in diffusion of the dye from the mitochondria and a
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Figure 4 Confocal microscopy indicates that survivin protein is taken up by cancer cellsand isnot merely binding to the cell surface. Cellswere fixed and
stained with antibodies to HA, with pictures taken on a z-scale of 1mm, magnification 1000. (A–J) are z-scale pictures taken at 1mm intervals as
represented in (K).
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Figure 11. Surv-T34A-conditioned medium induces tumor cell apoptosis whereas Surv-
WT-conditioned medium promotes cell growth. (A) Cervical carcinoma HeLa cells were 
grown in the presence of either Surv-T34A- or Surv-WT-conditioned medium for 24 and 
48 hrs., harvested and analyzed for DNA content by propidium iodide staining and flow 
cytometry (inset) or Trypan blue exclusion. Percentages of apoptotic cells with hypodip-
loid (sub-G1) DNA content are indicated per each condition tested. Data are 
representative of one of two or three independent experiments with comparable results. 
(B) HeLa cells, grown as described, were fixed with methanol and stained with crystal 
violet allowing visualization of the enhanced cellular proliferative effects of Surv-WT or 
the killing/growth-repressive effects of Surv-T34A. The data presented are the mean col-
ony formation efficiency ± S.D. in three experiments. (C) Mimosine-synchronized HeLa 
cells were harvested at the indicated increasing time intervals after release and analyzed 
for DNA content by propidium iodide staining and flow cytometry. A full color version 
of this figure is available at the British Journal of Cancer online.  
subsequent reduction in the mean red fluorescent intensity. As
expected, control HeLa cells showed a high mean red fluorescence
(set to B 96%) after staining with JC-1 (Figure 7C). After treatment
with staurosporine, we found that the mean red fluorescence of the
mitochondria dropped rapidly within 6h, indicating that the Dc m
had collapsed (Figure 7C). HeLa cells treated with Surv-T34A, but
not Surv-WT, showed a time-dependent reduction in the mean red
fluorescence intensity. However, in repeated xperiments this was
always slower than that seen for staurosporine (Figure 7C). This
may indicate that mitochondrial depolarisation due to Surv-T34A
is a secondary event and not the primary effect of Surv-T34A-
induced killing or that mitochondrial depolarisation is one of
many factors involved in Surv-T34A-induced killing.
Effect of Surv-T34A and Surv-WT and UV radiation on
tumour cell apoptosis
Incubation of HeLa cells with UV radiation resulted in enhanced
numbers of hypodiploid cells, which are sub-G1 DNA content or
apoptotic cells (Figure 8A) by DNA content analysis and flow
cytometry. In comparison to control cells that were set at B 5%,
UV radiation treatm nt resulted in 35% of the cells exhibiting a
sub-G1 DNA content. However, cells grown for 24h in Surv-WT-
CM before UV treatment were fully protected from the effects of
the UV energy. In turn, Surv-T34A enhanced the killing effects of
theUV and resulted in 75% of the cells exhibiting a sub-G1content
(Figure 8A).
Effect of Surv-T34A and Surv-WT and chemotherapeutic
drugs on tumour cell apoptosis
To establish that the effects recorded in HeLa cells were not
specific for this cell line alone or for UV radiation, we selected
human pancreatic adenocarcinoma (Capan1 and Capan2) cell lines
to study drug sensitivity and responsiveness in the presence or
absence of Surv-WT- and Surv-T34A-CM. Effects of taxol, 5-FU,
Ad, and CDPD were studied. Capan1 cells exhibited an enhanced
susceptibility to taxol, 5-FU, Ad, CDPD-induced cell death after the
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Figure 12.  Recombinant Survivin does not affect cell growth (Surv-WT) or life (Surv-
T34A).  HeLa cells were grown in increasing quantities of recombinant Surv-WT or 
Surv-T34A protein (1pg, 10pg, 100pg and 1ng) for 24 and 48 hours.  Cells were harvest-
ed, stained with Trypan blue and counted.  
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methods (Egorina, Sovershaev et al. 2005). HeLa cells were incubated with increasing 
concentrations of labeled recombinant protein, and the amount of protein endocytosed 
after a 12 hrs. incubation was measured as shown in Figure 13. The amount of transferrin 
and CTB proteins endocytosed increased in a dose-dependent manner. However, Survivin 
recombinant protein (BIRC5) at the same concentrations was not endocytosed (Figure 
13). Transferrin (Sandvig and van Deurs 1990) and CTB (Gizurarson, Tamura et al. 
1992, Frey, Giannasca et al. 1996, Hansen, Dalskov et al. 2005) recombinant proteins 
were previously described as substrates for endocytic uptake and were used as positive 
controls.  
 
Characterization of Tumor Cell Apoptosis Induced by Surv-T34A 
in vitro 
We have shown in Figures 7A and 11A that incubating HeLa cells with Surv-T34A-
CM resulted in apoptosis. Cytofluorometric quantification results showed that in compar-
ison with control media or Surv-WT-CM treatment, Surv-T34A treatments induced 
robust results within 24 to 48 hrs.. Previous studies performed, using an adenovirus-
encoding T34A mutant, resulted in apoptosis that was associated with the mitochondrial 
release of cytochrome c, cleavage of caspase-9, and the processing of caspase-3 (Mesri, 
Wall et al. 2001). Further analysis of Surv-T34A-CM-induced apoptosis, using a com-
mercially available caspase activity assay, revealed that Surv-T34A induced cleavage of 
caspase-9 and caspase-2 without cleaving the substrates specific for caspase-3 or caspase-
8 (Figure 14). The antibiotic and protein kinase inhibitor, staurosporine, was used as a 
positive control for caspase-3 activity. Surv-WT-CM had no effect on the caspase activity 
under evaluation. In addition, western blotting provided biochemical data that supported 
 50 
studies recorded above for caspase-2, caspase-3, and caspase-9. Using antibodies that 
were specific for the full-length, non-cleaved forms of caspase-2, caspase-7, and caspase-
9 and the cleaved form of caspase-3 protein and staurosporine again as a positive control, 
we found that Surv-T34A induced the parallel time-dependent reduction in caspase-2, 
caspase-7, caspase-9, and cleavage of the DNA repair protein PARP (Figure 15). In all 
cases the pan-caspase inhibitor Z-VAD-FMK was able to inhibit the activity of Surv-
T34A. In contrast, Surv-WT again had no observable effects on caspase cleavage when 
cells were treated with it alone for up to 48 hrs.. Caspase-3 was robustly cleaved after 6
hrs. of staurosporine treatment. However, this cleavage product was absent after 24 hrs. 
indicating a complete cleavage and degradation of caspase-3. Concomitant with this 
cleavage was the significant level of PARP cleavage recorded at this 24 hrs. time point. 
 
Loss of Mitochondrial Membrane Potential After Treatment  
with Surv-T34A CM 
Mitochondrial membrane potential (Δψm), a phenomenon readily measured using 
the mitochondrial dye JC-1 and fluorescence-activated cell sorting analysis (Salvioli, 
Ardizzoni et al. 1997), was evaluated for the possibility that Surv-T34A was stimulating 
apoptosis by inducing depolarization within the mitochondria. Under normal circum-
stances, JC-1 accumulates in the inner mitochondrial membrane in which it oligomerizes 
and fluoresces red. A reduction in Δψm results in diffusion of the dye from the mito-
chondria and a subsequent reduction in the mean red fluorescent intensity. As expected, 
control HeLa cells showed a high mean red fluorescence (set to ~96%) after staining with 
JC-1 (Figure 16). After treatment with staurosporine, we found that the mean red fluores-
cence of the mitochondria dropped rapidly within 6 h, indicating that the Δψm had  
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Figure 13. Recombinant Survivin protein is unable to cross the HeLa cell membrane. (A) 
Detection of cellular recombinant proteins. These images show a portion of a 96-well 
plate. The right panel is a composite image showing the fluorescence in both the 700- and 
800-nm detection channels. Duplicate rows of microplate wells loaded with 0.001, 0.01, 
or 1.0 μg of protein are shown. The middle panel shows detection of endogenous Sur-
vivin protein, which was used as a loading control. The left image shows detection of 
increasing amounts of recombinant Survivin (BIRC5), transferrin, and CTB. (B) Quanti-
fication of fluorescence. Recombinant protein signal has been normalised using the 
endogenous Survivin protein signal from each well to correct for well-to-well variation in 
cell number. Recombinant protein (rProtein).  
addition of Surv-T34A-CM, whereas Surv-WT-CM-incubated cells
were protected from taxol, 5-FU, and CDPD-induced cytotoxicity
(Figure 8B). Only a modest protection was recorded against Ad.
Interestingly, Surv-WT-CM treatment protected Capan2 cells from
the cytotoxic effects of 5-FU and again only a modest protection
was recorded against taxol, Ad, and CDPD. Treatment of Capan2
cells with Surv-T34A-CM was as effective as taxol, more effective
than CDPD and 5-FU and less effective as Ad alone. Surv-T34A
when combined with taxol showed an additional cytotoxicity that
may be quantitatively additive at best. When combined with
CDPD, Surv-T34A did not provide further enhancement to the
killing effects over that of Surv-T34A alone, which was substantial,
and when paired with 5-FU or Ad, the individual cytotoxic effects
of Surv-T34A were reduced (Figure 8C).
Survivin containing CM induces cancer cell invasion
in vitro
To determine the function of secreted survivin in regulating cancer
cell invasion through collagen, we plated HeLa cells on collagen-
coated inserts in the presence of control, Surv-WT-, or Surv-T34A-
CM. Cells were grown for 24h, dissociated, lysed, and then
evaluated for invasion by measuring the fluorescence emission
(CyQuant GR dye). HeLa cells exhibited an average fourfold
increase in cell invasion when grown with Surv-WT-CM in the
lower chamber as compared to control medium (Figure 9). Surv-
T34A-CM invasion levels were little changed from that of the
control as were those cells that were treated with medium that had
been depleted of survivin.
DISCUSSION
The growth and spread of cancer depends as much on the host
response to the tumour as on the biological characteristics of the
tumour itself. The IAP survivin has been shown aberrantly
expressed in cancer but undetectable in normal differentiated
adult tissue. It has been implicated in both control of apoptosis
(Ambrosini et al, 1997; Adida et al, 1998) and regulation of cell
division (Deveraux and Reed, 1999; Li et al, 1999; Gianani et al,
2001). Indeed, survivin expression has been shown to be cell-cycle
regulated with its highest expression in G2/M phase, and it has
been shown that much of its function comes from its subcellular
localisation with residences in the cytosol, nucleus, and mitochon-
dria (Li et al, 1999; Li, 2003). Recent reports on patients with
rheumatoid arthritis have described a new survivin localisation
and the possibility that it may also function in the extracellular
space (Bokarewa et al, 2005; Mera et al, 2008). Moreover, in these
patients, extracellular survivin was directly linked to an erosive
course of joint disease and its origin was prescribed to peripheral
blood leukocytes where its expression is constitutive. Furthermore,
survivin was shown to bind extracellularly to neutrophils inducing
the p38-MAPK-dependent expression of a- and b-integrins
(Mera et al, 2008). Taken together, the finding of a new and
physiologically functional pool of survivin provides new insight
into the function of IAPs as well as other relevant tumour-
associated proteins in the tumour microenvironment.
In this study we have shown that an extracellular form of
survivin is detectable in CM taken from cancer cells. We also
demonstrate that unlike survivin from the rheumatoid arthritis
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Figure 14. Conditioned medium containing Survivin affects the intrinsic apoptotic path-
way. Caspase catalytic activity. Aliquots of HeLa cells grown in the presence of either 
Surv-T34A- or Surv-WT-conditioned medium were assayed for caspase-3/7, caspase-8, 
caspase-9, and caspase-2 activity by Ac-DEVD-AMC, IETD-AMC, LEHD-AMC, and 
VDVAD-AMC hydrolysis, respectively, in the presence or absence of the caspase-3 in-
hibitor, DEVD-CHO; the caspase-8 inhibitor, IETD-fmk; the caspase-9 inhibitor, LEHD-
fmk; or the caspase-2 inhibitor, VDVAD-fmk. Inhibitor (INH), staurosporine (STR). Da-
ta are the mean±s.e. of two independent experiments.  
  
study, survivin from cancer cells is readily taken up by cancer cells
rather than binding only to their surface (Mera et al, 2008). Finally,
upon incubation in medium containing this extracellular pool of
survivin, cancer cells responded physiologically, becoming more
resistant to therapy, proliferating more rapidly, and having an
increased metastatic potential. These findings lead us to believe
that extracellular survivin may modulate, in vivo, the tumour
microenvironment for the purpose of tumour evolution and these
findings in part may be responsible for the observations that
patients with a high expression of survivin protein display
advanced disease, high-grade disease, abbreviated survival, resis-
tance to therapy, and accelerated tumour recurrences (Andersen
et al, 2007).
We have also shown that stable cells expressing the previously
described (Mesri et al, 2001; O’Connor et al, 2002) pro-apoptotic
survivin mutant Thr34- Ala (Surv-T34A) release a form of
survivin that is able to disrupt the cell cycle and cause a
caspase-dependent, mitochondrial depolarisation-associated apop-
tosis. When combined with UV radiation or with the chemo-
therapeutic agents taxol, Ad, CDPD, or 5-FU, Surv-T34As pro-
apoptotic ability was amplified. It was not surprising that these
modalities were differentially enhanced or inhibited by Surv-T34A
or Surv-WT because they have varied mechanisms of action. Surv-
T34A was found to be as effective in enhancing therapy-induced
cell killing as Surv-WT was in protecting against therapy-induced
cell killing. These differential effects seemed not to follow the
p53 status of the cell lines tested as Surv-WT was as effective
at protecting those cells lacking the tumour suppressor and
transcription factor as it was for those cells positive for p53. It
has been shown that survivin gene transcription is repressed by
WT p53 (Li, 2003) but little is known of p53’s ability to modify the
protein’s function. A more careful evaluation of this finding is
required.
The precise mechanism by which this survivin mutant causes
apoptosis is still incompletely understood. The mutations that
allowed for the generation of stable cells as well as their ability to
induce apoptosis through the caspase-2- and caspase-9-dependent
pathways are currently being evaluated in our laboratory.
Importantly, a quantifiable highly stable extracellular form of
survivin has been identified. This novel T34A survivin molecule is
readily taken up by cancer cells after which characteristics of
apoptotic cell death are measurable. Further, it potentiates the
killing effects of other cancer therapeutics. It is our belief that this
extracellular Surv-T34A molecule has significant potential as a
novel therapeutic or as part of a novel therapeutic and possible
immunotherapy regimen.
Tumour invasion and metastasis are very complex processes
that are yet very poorly understood but account for 90% of all
human cancer deaths (Sporn, 1996; Hanahan and Weinberg, 2000).
The mechanism involves coupling and uncoupling of cells to
their microenvironment, activation of extracellular proteases, and
modulation in tethering proteins such as cadherins, b-catenin, and
integrins (Hanahan and Weinberg, 2000). As survivin has already
been shown to modulate the integrin proteins CD49d, CD11b, and
A
R
e
la
ti
v
e
 f
lu
o
re
s
c
e
n
t 
u
n
it
s
Casp 3/7
B T
34
A
+z
va
d
Caspase 9
PARP
Caspase 7
Mrx10
3
2
4
 h
4
8
 h
6
 h
2
4
 h
2
4
 h
4
8
 h
2
4
 h
4
8
 h
4
8
 h
C
on
tr
ol
S
ta
ur
os
po
rin
e
T
34
A
W
T
37
25
48
37
115
89
48
37
Caspase 2
GAPDH
48
37
25
19
Caspase 3
(Cleaved)
1
.0
1
.0
1
.0
0
.4
1
.0
0
.5
1
.0
0
.9
1
.0
1
.0
1
.0
0
.8
0
.5
0
.7
0
.4
1
.1
1
.1
1
.2
1
.0
1
.0
0
.9
0
.3
0
.7
0
.7
1
.0
1
.1
1
.2
C
0
5
10
15
20
25
30
C
on
tro
l
S
ta
ur
os
po
rin
e
24
 h
48
 h
24
 h
48
 h
Surv-T34A
P
e
rc
e
n
t 
d
e
p
o
l a
ri
z
a
ti
o
n
12 000
10 000
8000
6000
4000
2000
0
Casp 2Casp 9Casp 8
Surv-WT
Negative control
Staurosporine
Inhibitor
Surv-WT
Surv-T34A
Figure 7 Conditioned medium containing survivin affects the intrinsic
apoptotic pathway. (A) Caspase catalytic activity. Aliquots of HeLa cells
grown in the presence of either Surv-T34A- or Surv-WT-conditioned
medium were assayed for caspase-3/7, caspase-8, caspase-9, and caspase-2
activity by Ac-DEVD-AMC, IETD-AMC, LEHD-AMC, and VDVAD-AMC
hydrolysis, respectively, in the presence or absence of the caspase-3
inhibitor, DEVD-CHO; the caspase-8 inhibitor, IETD-fmk; the caspase-9
inhibitor, LEHD-fmk; or the caspase-2 inhibitor, VDVAD-fmk. Inhibitor
(INH), staurosporine (STR). Data are the mean± s.e. of two independent
experiments. (B) Caspase activation. Detergent-solubilised extracts of
HeLa cells grown in Surv-WT- or Surv-T34A-conditioned medium were
analysed at the indicated time intervals for reactivity with antibodies for
caspase-2, caspase-3, caspase-7, caspase-9, PARP, and GAPDH (loading
control) by western blotting. Molecular weight (Mr) markers in kilodaltons
are shown on the left. Densitometric analysis was conducted on caspase-2,
caspase-7, and caspase-9 with their densities as compared to GAPDH
located below each blot. (C) Mitochondrial depolarisation. The experi-
mental conditions are the same as in B, except that HeLa cells grown in
Surv-WT- or Surv-T34A-conditioned medium were analysed at the
indicated time intervals using the mitochondrial membrane potential
monitoring agent JC-1. A reduction in Dc m results in diffusion of the dye
from the mitochondria and a subsequent reduction in the mean red
fluorescent intensity, which is quantifiable using flow cytometry. Stauro-
sporine treatment for 6h is used as a positive control. Data are the
mean± s.e. of two independent experiments.
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Figure 15. Caspase activation. Detergent-solubilized extracts of HeLa cells grown in 
Surv-WT- or Surv-T34A-conditioned medium were analyzed at the indicated time inter-
vals for reactivity with antibodies for caspase-2, caspase-3, caspase-7, caspase-9, PARP, 
and GAPDH (loading control) by western blotting. Molecular weight (Mr) markers in 
kilodaltons are shown on the left. Densitometric analysis was conducted on caspase-2, 
caspase-7, and caspase-9 with their densities as compared to GAPDH located below each 
blot.  
  
study, survivin from cancer cells is readily taken up by cancer cells
rather than binding only to their surface (Mera et al, 2008). Finally,
upon incubation in medium containing this extracellular pool of
survivin, cancer cells responded physiologically, becoming more
resistant to therapy, proliferating more rapidly, and having an
increased metastatic potential. These findings lead us to believe
that extracellular survivin may modulate, in vivo, the tumour
microenvironment for the purpose of tumour evolution and these
findings in part may be responsible for the observations that
patients with a high expression of survivin protein display
advanced disease, high-grade disease, abbreviated survival, resis-
tance to therapy, and accelerated tumour recurrences (Andersen
et al, 2007).
We have also shown that stable cells expressing the previously
described (Mesri et al, 2001; O’Connor et al, 2002) pro-apoptotic
survivin mutant Thr34- Ala (Surv-T34A) release a form of
survivin that is able to disrupt the cell cycle and cause a
caspase-dependent, mitochondrial depolarisation-associated apop-
tosis. When combined with UV radiation or with the chemo-
therapeutic agents taxol, Ad, CDPD, or 5-FU, Surv-T34As pro-
apoptotic ability was amplified. It was not surprising that these
modalities were differentially enhanced or inhibited by Surv-T34A
or Surv-WT because they have varied mechanisms of action. Surv-
T34A was found to be as effective in enhancing therapy-induced
cell killing as Surv-WT was in protecting against therapy-induced
cell killing. These differential effects seemed not to follow the
p53 status of the cell lines tested as Surv-WT was as effective
at protecting those cells lacking the tumour suppressor and
transcription factor as it was for those cells positive for p53. It
has been shown that survivin gene transcription is repressed by
WT p53 (Li, 2003) but little is known of p53’s ability to modify the
protein’s function. A more careful evaluation of this finding is
required.
The precise mechanism by which this survivin mutant causes
apoptosis is still incompletely understood. The mutations that
allowed for the generation of stable cells as well as their ability to
induce apoptosis through the caspase-2- and caspase-9-dependent
pathways are currently being evaluated in our laboratory.
Importantly, a quantifiable highly stable extracellular form of
survivin has been identified. This novel T34A survivin molecule is
readily taken up by cancer cells after which characteristics of
apoptotic cell death are measurable. Further, it potentiates the
killing effects of other cancer therapeutics. It is our belief that this
extracellular Surv-T34A molecule has significant potential as a
novel therapeutic or as part of a novel therapeutic and possible
immunotherapy regimen.
Tumour invasion and metastasis are very complex processes
that are yet very poorly understood but account for 90% of all
human cancer deaths (Sporn, 1996; Hanahan and Weinberg, 2000).
The mechanism involves coupling and uncoupling of cells to
their microenvironment, activation of extracellular proteases, and
modulation in tethering proteins such as cadherins, b-catenin, and
integrins (Hanahan and Weinberg, 2000). As survivin has already
been shown to modulate the integrin proteins CD49d, CD11b, and
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Figure 7 Conditioned medium containing survivin affects the intrinsic
apoptotic pathway. (A ) Caspase catalytic activity. Aliquots of HeLa cells
grown in the presence of either Surv-T34A- or Surv-WT-conditioned
medium were assayed for caspase-3/7, caspase-8, caspase-9, and caspase-2
activity by Ac-DEVD-AMC, IETD-AMC, LEHD-AMC, and VDVAD-AMC
hydrolysis, respectively, in the presence or absence of the caspase-3
inhibitor, DEVD-CHO; the caspase-8 inhibitor, IETD-fmk; the caspase-9
inhibitor, LEHD-fmk; or the caspase-2 inhibitor, VDVAD-fmk. Inhibitor
(INH), staurosporine (STR). Data are the mean± s.e. of two independent
experiments. (B) Caspase activation. Detergent-solubilised extracts of
HeLa cells grown in Surv-WT- or Surv-T34A-conditioned medium were
analysed at the indicated time intervals for reactivity with antibodies for
caspase-2, caspase-3, caspase-7, caspase-9, PARP, and GAPDH (loading
control) by western blotting. Molecular weight (Mr) markers in kilodaltons
are shown on the left. Densitometric analysis was conducted on caspase-2,
caspase-7, and caspase-9 with their densities as compared to GAPDH
located below each blot. (C) Mitochondrial depolarisation. The experi-
mental conditions are the same as in B, except that HeLa cells grown in
Surv-WT- or Surv-T34A-conditioned medium were analysed at the
indicated time intervals using the mitochondrial membrane potential
monitoring agent JC-1. A reduction in Dc m results in diffusion of the dye
from the mitochondria and a subsequent reduction in the mean red
fluorescent intensity, which is quantifiable using flow cytometry. Stauro-
sporine treatment for 6h is used as a positive control. Data are the
mean± s.e. of two independent experiments.
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Figure 16. Mitochondrial depolarization. The experimental conditions are the same as in 
B, except that HeLa cells grown in Surv-WT- or Surv-T34A-conditioned medium were 
analyzed at the indicated time intervals using the mitochondrial membrane potential mon-
itoring agent JC-1. A reduction in Δψm results in diffusion of the dye from the 
mitochondria and a subsequent reduction in the mean red fluorescent intensity, which is 
quantifiable using flow cytometry. Staurosporine treatment for 6 h is used as a positive 
control. Data are the mean±s.e. of two independent experiments.  
study, survivin from cancer cells is readily taken up by cancer cells
rather than binding only to their surface (Mera et al, 2008). Finally,
upon incubation in medium containing this extracellular pool of
survivin, cancer cells responded physiologically, becoming more
resistant to therapy, proliferating more rapidly, and having an
increased metastatic potential. These findings lead us to believe
that extracellular survivin may modulate, in vivo, the tumour
microenvironment for the purpose of tumour evolution and these
findings in part may be responsible for the observations that
patients with a high expression of survivin protein display
advanced disease, high-grade disease, abbreviated survival, resis-
tance to therapy, and accelerated tumour recurrences (Andersen
et al, 2007).
We have also shown that stable cells expressing the previously
described (Mesri et al, 2001; O’Connor et al, 2002) pro-apoptotic
survivin mutant Thr34- Ala (Surv-T34A) release a form of
survivin that is able to disrupt the cell cycle and cause a
caspase-dependent, mitochondrial depolarisation-associated apop-
tosis. When combined with UV radiation or with the chemo-
therapeutic agents taxol, Ad, CDPD, or 5-FU, Surv-T34As pro-
apoptotic ability was amplified. It was not surprising that these
modalities were differentially enhanced or inhibited by Surv-T34A
or Surv-WT because they have varied mechanisms of action. Surv-
T34A was found to be as effective in enhancing therapy-induced
cell killing as Surv-WT was in protecting against therapy-induced
cell killing. These differential effects seemed not to follow the
p53 status of the cell lines tested as Surv-WT was as effective
at protecting those cells lacking the tumour suppressor and
transcription factor as it was for those cells positive for p53. It
has been shown that survivin gene transcription is repressed by
WT p53 (Li, 2003) but little is known of p53’s ability to modify the
protein’s function. A more careful evaluation of this finding is
required.
The precise mechanism by which this survivin mutant causes
apoptosis is still incompletely understood. The mutations that
allowed for the generation of stable cells as well as their ability to
induce apoptosis through the caspase-2- and caspase-9-dependent
pathways are currently being evaluated in our laboratory.
Importantly, a quantifiable highly stable extracellular form of
survivin has been identified. This novel T34A survivin molecule is
readily taken up by cancer cells after which characteristics of
apoptotic cell death are measurable. Further, it potentiates the
killing effects of other cancer therapeutics. It is our belief that this
extracellular Surv-T34A molecule has significant potential as a
novel therapeutic or as part of a novel therapeutic and possible
immunotherapy regimen.
Tumour invasion and metastasis are very complex processes
that are yet very poorly understood but account for 90% of all
human cancer deaths (Sporn, 1996; Hanahan and Weinberg, 2000).
The mechanism involves coupling and uncoupling of cells to
their microenvironment, activation of extracellular proteases, and
modulation in tethering proteins such as cadherins, b-catenin, and
integrins (Hanahan and Weinberg, 2000). As survivin has already
been shown to modulate the integrin proteins CD49d, CD11b, and
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Figure 7 Conditioned medium containing survivin affects the intrinsic
apoptotic pathway. (A) Caspase catalytic activity. Aliquots of HeLa cells
grown in the presence of either Surv-T34A- or Surv-WT-conditioned
medium were assayed for caspase-3/7, caspase-8, caspase-9, and caspase-2
activity by Ac-DEVD-AMC, IETD-AMC, LEHD-AMC, and VDVAD-AMC
hydrolysis, respectively, in the presence or absence of the caspase-3
inhibitor, DEVD-CHO; the caspase-8 inhibitor, IETD-fmk; the caspase-9
inhibitor, LEHD-fmk; or the caspase-2 inhibitor, VDVAD-fmk. Inhibitor
(INH), staurosporine (STR). Data are the mean± s.e. of two independent
experiments. (B) Caspase activation. Detergent-solubilised extracts of
HeLa cells grown in Surv-WT- or Surv-T34A-conditioned medium were
analysed at the indicated time intervals for reactivity with antibodies for
caspase-2, caspase-3, caspase-7, caspase-9, PARP, and GAPDH (loading
control) by western blotting. Molecular weight (Mr) markers in kilodaltons
are shown on the left. Densitometric analysis was conducted on caspase-2,
caspase-7, and caspase-9 with their densities as compared to GAPDH
located below each blot. (C) Mitochondrial depolarisation. The experi-
mental conditions are the same as in B, except that HeLa cells grown in
Surv-WT- or Surv-T34A-conditioned medium were analysed at the
indicated time intervals using the mitochondrial membrane potential
monitoring agent JC-1. A reduction in Dc m results in diffusion of the dye
from the mitochondria and a subsequent reduction in the mean red
fluorescent intensity, which is quantifiable using flow cytometry. Stauro-
sporine treatment for 6h is used as a positive control. Data are the
mean± s.e. of two independent experiments.
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collapsed (Figure 16). HeLa cells treated with Surv-T34A, but not Surv-WT, showed a 
time-dependent reduction in the mean red fluorescence intensity. However, in repeated 
experiments this was always slower than that seen for staurosporine (Figure 16). This 
may indicate that mitochondrial depolarisation due to Surv-T34A is a secondary event 
and not the primary effect of Surv-T34A-induced killing or that mitochondrial depolari-
zation is one of many factors involved in Surv-T34A-induced killing. 
 
Effect of Surv-T34A and Surv-WT and UV Radiation  
on Tumor Cell Apoptosis 
Incubation of HeLa cells with UV radiation resulted in enhanced numbers of hy-
podiploid cells, which are sub-G1 DNA content or apoptotic cells (Figure 17A) by DNA 
content analysis and flow cytometry. In comparison to control cells that were set at ~5%, 
UV radiation treatment resulted in 35% of the cells exhibiting a sub-G1 DNA content. 
However, cells grown for 24 hrs. in Surv-WT-CM before UV treatment were fully pro-
tected from the effects of the UV energy. In turn, Surv-T34A enhanced the killing effects 
of the UV and resulted in 75% of the cells exhibiting a sub-G1 content (Figure 17A). 
 
Effect of Surv-T34A and Surv-WT and Chemotherapeutic  
Drugs on Tumor Cell Apoptosis 
To establish that the effects recorded in HeLa cells were not specific for this cell line 
alone or for UV radiation, we selected human pancreatic adenocarcinoma (Capan1 and 
Capan2) cell lines to study drug sensitivity and responsiveness in the presence or absence 
of Surv-WT- and Surv-T34A-CM. Effects of taxol, 5-FU, Ad, and CDPD were studied. 
Capan1 cells exhibited an enhanced susceptibility to taxol, 5-FU, Ad, CDPD-induced cell 
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death after the addition of Surv-T34A-CM, whereas Surv-WT-CM-incubated cells were 
protected from taxol, 5-FU, and CDPD-induced cytotoxicity (Figure 17B). Only a modest 
protection was recorded against Ad. Interestingly, Surv-WT-CM treatment protected Ca-
pan2 cells from the cytotoxic effects of 5-FU and again only a modest protection was 
recorded against taxol, Ad, and CDPD. Treatment of Capan2 cells with Surv-T34A-CM 
was as effective as taxol, more effective than CDPD and 5-FU and less effective as Ad 
alone. Surv-T34A when combined with taxol showed an additional cytotoxicity that may 
be quantitatively additive at best. When combined with CDPD, Surv-T34A did not pro-
vide further enhancement to the killing effects over that of Surv-T34A alone, which was 
substantial, and when paired with 5-FU or Ad, the individual cytotoxic effects of Surv-
T34A were reduced (Figure 17C). 
 
Survivin Containing CM Induces Cancer Cell Invasion in vitro 
To determine the function of secreted Survivin in regulating cancer cell invasion 
through collagen, we plated HeLa cells on collagen-coated inserts in the presence of con-
trol, Surv-WT-, or Surv-T34A-CM. Cells were grown for 24 h, dissociated, lysed, and 
then evaluated for invasion by measuring the fluorescence emission (CyQuant GR dye). 
HeLa cells exhibited an average fourfold increase in cell invasion when grown with Surv-
WT-CM in the lower chamber as compared to control medium (Figure 18). Surv-T34A-
CM invasion levels were little changed from that of the control as were those cells that 
were treated with medium that had been depleted of Survivin. 
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Figure 17. Effect of Surv-WT and Surv-T34A and UV (A) or chemotherapeutic drugs (B 
and C) on tumor cell apoptosis. Aliquots of HeLa cells were treated with UV (50 J/m2) 
(A) or Capan1 (B) and Capan2 (C) cells were treated with Adriamycin (Ad; 100 nm), 5-
fluorouracil (5-FU; 200 nm), taxol (4 μm), or cisplatin (CDPD; 2 μm) in the presence or 
absence of Surv-WT- or Surv-T34A-conditioned medium. Cells were harvested at 48 hrs. 
and apoptosis was determined by DNA content analysis and flow cytometry. The time 
point of combination treatments is 48 hrs. after the addition of the drug following a 24 
hrs. pretreatment in the conditioned medium. Data are representative of one of two inde-
pendent experiments with comparable results.  
CD11c on leukocytes (Mera et al, 2008), we hypothesised that it
may also modulate the invasive capabilities of cancer cells. In our
hands Surv-WT-CM s imulated 3- to 4-fold increase in collagen
invasion in comparison with the control medium alone or medium
containing Surv-T34A. Medium depleted of survivin using
antibodies first that r cognised the fusion proteins Flag and HA
and then oneand three rounds of anti-survivin antibody depletion,
completely inhibited survivin-induced collagen invasion thus
placing survivin as a central player in this increased metastatic
potential.
Stress-induced cancer cell death by means of apoptosis,
necrosis, and autophagy occurs continually during tumour
development and progression (Fonseca and Dranoff, 2008). What
the ramifications of this to th tumour microenvironment is only
beginning to be evaluated. It is believed that the capture of
apoptotic cells serves as an immunoregulatory event that helps
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Figure 8 Effect of Surv-WT and Surv-T34A and UV (A) or chemotherapeutic drugs (B and C) on tumour cell apoptosis. Aliquots of HeLa cells were
treated with UV (50Jm 2) (A) or Capan1 (B) and Capan2 (C) cellswere treated with Adriamycin (Ad; 100nM), 5-fluorouracil (5-FU; 200nM), taxol (4mM),
or cisplatin (CDPD; 2mM) in the presence or absence of Surv-WT- or Surv-T34A-conditioned medium. Cells were harvested at 48h and apoptosis was
determined by DNA c tent analysis and flow cytometry. The time p int of combination treatments is 48h after the addition of the drug following a 24-h
pretreatment in the conditioned medium. Data are representative of one of two independent experiments with comparable results.
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Discussion 
The growth and spread of cancer depends as much on the host response to the tumor as 
on the biological characteristics of the tumor itself. The IAP Survivin has been shown 
aberrantly expressed in cancer but undetectable in normal differentiated adult tissue. It 
has been implicated in both control of apoptosis (Ambrosini, Adida et al. 1997, Adida, 
Crotty et al. 1998)and regulation of cell division (Deveraux and Reed 1999, Li, 
Ackermann et al. 1999, Gianani, Jarboe et al. 2001). . Indeed, Survivin expression has 
been shown to be cell cycle regulated with its highest expression in G2/M phase, and it 
has been shown that much of its function comes from its subcellular localization with res-
idences in the cytosol, nucleus, and mitochondria (Li, Ackermann et al. 1999, Li 2003). 
Recent reports on patients with rheumatoid arthritis have described a new Survivin local-
ization and the possibility that it may also function in the extracellular space (Bokarewa, 
Lindblad et al. 2005, Mera, Magnusson et al. 2008). Moreover, in these patients, extracel-
lular Survivin was directly linked to an erosive course of joint disease and its origin was 
prescribed to peripheral blood leukocytes where its expression is constitutive. Further-
more, Survivin was shown to bind extracellularly to neutrophils inducing the p38-
MAPK-dependent expression of α- and β-integrins (Mera, Magnusson et al. 2008). Taken 
together, the finding of a new and physiologically functional pool of Survivin provides 
new insight into the function of IAPs as well as other relevant tumor-associated proteins 
in the tumor microenvironment. 
In this study we have shown that an extracellular form of Survivin is detectable in 
CM taken from cancer cells. We also demonstrate that unlike Survivin from the rheuma-
toid arthritis study, Survivin from cancer cells is readily taken up by cancer cells rather  
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Figure 18. Effect of Surv-WT and Surv-T34A on tumor cell invasion. HeLa cells (1 × 
105 cells) were seeded into the upper well of the FIA chamber in 100 μl culture medium. 
Cells were treated with the presence of Surv-WT- or Surv-T34A-conditioned medium, 
medium depleted of Survivin using two rounds of fusion protein antibodies (anti-Flag and 
anti-HA) and one or three rounds of Survivin antibodies in the lower chamber and incu-
bated at 37°C in an atmosphere of 5% CO2. After 24 hrs. of incubation, we lysed and 
quantitatively analyzed fluorescence intensity of invasive cells that passed through the 
collagen layer onto the surface of the fluorescence-blocking membrane, giving relative 
fluorescent units (RFU). Data are the mean±s.d. of four independent experiments 
(*P<0.01).  
maintain tolerance whereas necrotic cells evoke an inflammatory
cascade that mobilises effector responses. On the basis of our
findings, we postulate that many of these released cancer antigens
could in addition to modulating immune function prime the cells
within the tumour microenvironment for the phenotypes asso-
ciated with tumour invasion and metastasis that are listed above.
Survivin expression in CM was measured extracellularly using
ELISA. It is not known whether extracellular survivin originates
from dead cells or is the subject of active secretion. Comparing
survivin quantity from 1 to 10% lysates to that of CM argues for
active secretion rather than necrosis as SaOS2, Capan1, and HeLa-S-
Surv-WT cells all have equal or more survivin protein but yet have
no dead or dying cells as determined visually and by Trypan blue
exclusion. Importantly, survivin found extracellularly creates a more
erosivediseasein patientswith rheumatoid arthritis (Bokarewaet al,
2005) and in our cancer cell culture models, parameters that are
considered clinically unfavourable in cancer patients: proliferative
advantage, enhanced resistance to therapy, and enhanced metastatic
potential. Investigating recombinant survivin’sability to recapitulate
the effects recorded using CM-containing survivin proved unpro-
fitable. From these experiments, we conclude that the survivin
recombinant protein, which hasbeen severed from itsGST handle, is
unable to induce similar phenotypes as the CM-containing survivin
as it isunable to enter thecancer cells. Further studiesusing circular
dichroism mass spectrometry will be required to compare these two
forms of survivin to define differences in structure and or
posttranslational modifications that may aid survivin in binding
with its yet to be defined receptor or trafficking proteins.
A deeper understanding of the mechanisms underlying this
extracellular pool of survivin, the possible ramifications for
tumourigenesis, and the possibility of exploiting it for therapy
are only a few of the many properties of this most fascinating of
proteins that we are continuing to evaluate.
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Fi re 9 Effect of Surv-WT and Surv-T34A on tumour c ll inva ion.
HeLa cells (1 105 cells) were seeded into the upper well of the FIA
chamber in 100ml culture m dium. Cellswere treated with the pr sence of
Surv-WT- or Surv-T34A-conditioned medium, medium depleted of
survivin using two rounds of fusion protein antibodies (anti-Flag and anti-
HA) and one or three rounds of survivin antibodies in the lower chamber
and incubated at 371C in an atmosphere of 5% CO2. After 24h of
incubation, we lysed and qu ntitatively analysed fl oresce c intensity of
invasive cells that passed through the collagen layer onto the surface of the
fluorescence-blocking membrane, giving relative fluorescent units (RFU).
Data are the mean± s.d. of four independent experiments (*Po 0.01).
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than binding only to their surface (Mera, Magnusson et al. 2008). Finally, upon incuba-
tion in medium containing this extracellular pool of Survivin, cancer cells responded 
physiologically, becoming more resistant to therapy, proliferating more rapidly, and hav-
ing an increased metastatic potential. These findings lead us to believe that extracellular 
Survivin may modulate, in vivo, the tumor microenvironment for the purpose of tumor 
evolution and these findings in part may be responsible for the observations that patients 
with a high expression of Survivin protein display advanced disease, high-grade disease, 
abbreviated survival, resistance to therapy, and accelerated tumor recurrences (Andersen, 
Svane et al. 2007). 
We have also shown that stable cells expressing the previously described (Mesri, 
Wall et al. 2001, O'Connor, Wall et al. 2002) pro-apoptotic Survivin mutant Thr34 → 
Ala (Surv-T34A) release a form of Survivin that is able to disrupt the cell cycle and cause 
a caspase-dependent, mitochondrial depolarization-associated apoptosis. When combined 
with UV radiation or with the chemotherapeutic agents taxol, Ad, CDPD, or 5-FU, Surv-
T34As pro-apoptotic ability was amplified. It was not surprising that these modalities 
were differentially enhanced or inhibited by Surv-T34A or Surv-WT because they have 
varied mechanisms of action. Surv-T34A was found to be as effective in enhancing ther-
apy-induced cell killing as Surv-WT was in protecting against therapy-induced cell 
killing. These differential effects seemed not to follow the p53 status of the cell lines test-
ed as Surv-WT was as effective at protecting those cells lacking the tumor suppressor and 
transcription factor as it was for those cells positive for p53. It has been shown that Sur-
vivin gene transcription is repressed by WT p53 (Li 2003)but little is known of p53's 
ability to modify the protein's function. A more careful evaluation of this finding is re-
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quired. 
The precise mechanism by which this Survivin mutant causes apoptosis is still in-
completely understood. The mutations that allowed for the generation of stable cells as 
well as their ability to induce apoptosis through the caspase-2- and caspase-9-dependent 
pathways are currently being evaluated in our laboratory. Importantly, a quantifiable 
highly stable extracellular form of Survivin has been identified. This novel T34A Sur-
vivin molecule is readily taken up by cancer cells after which characteristics of apoptotic 
cell death are measurable. Further, it potentiates the killing effects of other cancer thera-
peutics. It is our belief that this extracellular Surv-T34A molecule has significant 
potential as a novel therapeutic or as part of a novel therapeutic and possible immuno-
therapy regimen. 
Tumor invasion and metastasis are very complex processes that are yet very poor-
ly understood but account for 90% of all human cancer deaths (Sporn 1996, Hanahan and 
Weinberg 2000). The mechanism involves coupling and uncoupling of cells to their mi-
croenvironment, activation of extracellular proteases, and modulation in tethering 
proteins such as cadherins, β-catenin, and integrins (Hanahan and Weinberg 2000). As 
Survivin has already been shown to modulate the integrin proteins CD49d, CD11b, and 
CD11c on leukocytes (Mera, Magnusson et al. 2008), we hypothesized that it may also 
modulate the invasive capabilities of cancer cells. In our hands Surv-WT-CM stimulated 
a 3- to 4-fold increase in collagen invasion in comparison with the control medium alone 
or medium containing Surv-T34A. Medium depleted of Survivin using antibodies first 
that recognized the fusion proteins Flag and HA and then one and three rounds of anti-
Survivin antibody depletion, completely inhibited Survivin-induced collagen invasion 
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thus placing Survivin as a central player in this increased metastatic potential. 
Stress-induced cancer cell death by means of apoptosis, necrosis, and autophagy 
occurs continually during tumor development and progression (Fonseca and Dranoff 
2008). What the ramifications of this to the tumor microenvironment is only beginning to 
be evaluated. It is believed that the capture of apoptotic cells serves as an immunoregula-
tory event that helps maintain tolerance whereas necrotic cells evoke an inflammatory 
cascade that mobilizes effector responses. On the basis of our findings, we postulate that 
many of these released cancer antigens could in addition to modulating immune function 
prime the cells within the tumor microenvironment for the phenotypes associated with 
tumor invasion and metastasis that are listed above. 
Survivin expression in CM was measured extracellularly using ELISA. It is not 
known whether extracellular Survivin originates from dead cells or is the subject of ac-
tive secretion. Comparing Survivin quantity from 1 to 10% lysates to that of CM argues 
for active secretion rather than necrosis as SaOS2, Capan1, and HeLa-S-Surv-WT cells 
all have equal or more Survivin protein but yet have no dead or dying cells as determined 
visually and by Trypan blue exclusion. Importantly, Survivin found extracellularly cre-
ates a more erosive disease in patients with rheumatoid arthritis (Bokarewa, Lindblad et 
al. 2005) and in our cancer cell culture models, parameters that are considered clinically 
unfavorable in cancer patients: proliferative advantage, enhanced resistance to therapy, 
and enhanced metastatic potential. Investigating recombinant Survivin's ability to reca-
pitulate the effects recorded using CM-containing Survivin proved unprofitable. From 
these experiments, we conclude that the Survivin recombinant protein, which has been 
severed from its GST handle, is unable to induce similar phenotypes as the CM-
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containing Survivin as it is unable to enter the cancer cells. Further studies using circular 
dichroism mass spectrometry will be required to compare these two forms of Survivin to 
define differences in structure and or posttranslational modifications that may aid Sur-
vivin in binding with its yet to be defined receptor or trafficking proteins. 
A deeper understanding of the mechanisms underlying this extracellular pool of 
Survivin, the possible ramifications for tumorigenesis, and the possibility of exploiting it 
for therapy are only a few of the many properties of this most fascinating of proteins that 
we are continuing to evaluate. 
 
Acknowledgements 
This study was supported by NCMHD Project EXPORT Program 
5P20MD001632/Project 3 (NR Wall). This work was also funded as part of a start-up 
package by Loma Linda University's Center for Molecular Biology and Gene Therapy, 
now the Center for Health Disparities Research and Molecular Medicine (NRW), and by 
the Hirschberg Pancreatic Cancer Foundation (NRW). We thank Drs Viven Mao and 
Laura Green for help with the confocal microscopy, Dalmor McGregor for making the 
Survivin recombinant protein, and Nic Galloway and Jessica Slater for reviewing this ar-
ticle. 
 
  
 64 
 
 
CHAPTER THREE 
ENHANCEMENT OF GEMCITABINE SENSITIVITY IN 
PANCREATIC ADENOCARCINOMA BY NOVEL EXOSOME-
MEDIATED DELIVERY OF THE SURVIVIN-T34A MUTANT. 
 
 
Jonathan R. Aspe BS, Carlos J. Diaz Osterman BS, Jessica M.S. Jutzy PhD, Simone 
DeShields, Sonia Whang BS and Nathan R. Wall PhD, MS, MBA* 
 
 
 
Center for Health Disparities & Molecular Medicine 
Department of Basic Sciences/Division of Biochemistry & Microbiology 
Loma Linda University 
Loma Linda, California 92350 
 
 
Running title:  Exosome therapy and pancreatic cancer. 
 
 
Adapted from Aspe, J.R., Diaz Osterman, C.J., Jutzy, J.M.S., DeShields, S., and Wall, 
N.R. Journal of Extracellular Vesicles (2014) 
 65 
Abstract 
Background 
Current therapeutic options for advanced pancreatic cancer have been largely dis-
appointing with modest results at best, and though adjuvant therapy remains 
controversial, most remain in agreement that Gemcitabine should stand as part of any 
combination study. The inhibitor of apoptosis (IAP) protein Survivin is a key factor in 
maintaining apoptosis resistance, and its dominant-negative mutant (Survivin-T34A) has 
been shown to block Survivin, inducing caspase activation and apoptosis.  
 
Methods 
In this study, exosomes, collected from a melanoma cell line built to harbor a tet-
racycline-regulated Survivin-T34A, were plated on the pancreatic adenocarcinoma (MIA 
PaCa-2) cell line. Evaluation of the presence of Survivin-T34A in these exosomes fol-
lowed by their ability to induce Gemcitabine-potentiative cell killing was the objective of 
this work. 
 
Results 
Here we show that exosomes collected in the absence of tetracycline (tet-off) 
from the engineered melanoma cell do contain Survivin-T34A and when used alone or in 
combination with Gemcitabine, induced a significant increase in apoptotic cell death 
when compared to Gemcitabine alone on a variety of pancreatic cancer cell lines.  
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Conclusion 
This exosomes/Survivin-T34A study shows that a new delivery method for anti-
cancer proteins within the cancer microenvironment may prove useful in targeting 
cancers of the pancreas. 
 
Keywords:  Survivin, Survivin-T34A, exosomes, pancreatic cancer, Gemcitabine 
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Introduction 
Pancreatic cancer is the fourth leading cause of cancer death in the United States, 
with an average 5-year survival rate of 5% for all stages of the disease (Kleeff, Michalski 
et al. 2006). Pancreatic cancer has an annual mortality rate of approximately 95% with 
over 250,000 patients dying worldwide (Jemal, Bray et al. 2011). Pancreatic cancer ex-
hibits no clear early warning signs or symptoms and it is often detected after it is too late 
for pancreatic resection. Currently, if diagnosed at early stages, surgical resection remains 
the most efficacious treatment and offers the best patient outcome. However, only 20% of 
pancreatic cancer patients meet these criteria (Muller, Friess et al. 2008). There is a need 
to discover and implement new therapies or therapeutic combinations that increase the 
survival rate of those afflicted with this pancreatic cancer. Gemcitabine remains the gold-
standard for chemotherapy (Ueno, Kiyosawa et al. 2007). However, while Gemcitabine 
has shown significant benefit in clinical applications, its ability to effectively impact pan-
creatic cancer is limited. Currently, combinatory treatments using Gemcitabine and other 
therapeutics have shown no significant improvements in survival rates (Oettle and 
Neuhaus 2007, Reni, Cereda et al. 2007, Galloway, Aspe et al. 2009). However, the can-
cer research field is moving rapidly towards combinatorial therapies including combined 
multiple chemotherapy drugs (Vishnu, Colon-Otero et al. 2012), radiation with chemo-
therapy (Galloway, Aspe et al. 2009), and virotherapy with chemotherapy 
(Karapanagiotou, Roulstone et al. 2012). The IAP Survivin seems to be one of the key 
players in resistance to many of these cancer therapies (Asanuma, Kobayashi et al. 2002, 
Li 2003, Kami, Doi et al. 2005) and therefore a strategy to inhibit its action, when com-
bined with standard treatment options may prove beneficial. 
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Survivin is a possible prognostic marker for pancreatic cancer patients (Satoh, 
Kaneko et al. 2001, Sarela, Verbeke et al. 2002, Kami, Doi et al. 2004). Though ex-
pressed in most human cancers and present during embryonic and fetal development 
(Adida, Crotty et al. 1998), its aberrantly high protein expression in cancer cells and low 
level of expression in most normal tissues makes Survivin an important anticancer target 
(Fukuda and Pelus 2006). Survivin overexpression in cancer has been described as a pre-
dictive factor in determining response to chemotherapy and radiotherapy (Galloway, 
Aspe et al. 2009, Zhu, Wang et al. 2011, Shen, Zheng et al. 2012). Survivin reduces cell 
death induced by several anticancer agents including paclitaxel, etoposide and tumor ne-
crosis factor alpha. Conversely, inhibition of Survivin reduces tumor growth potential 
and sensitizes tumor cells to many of the same chemotherapeutic agents (Mita, Mita et al. 
2008).  
We have reported a marked enhancement of Survivin’s role in therapeutic re-
sistance to both chemo- and radiotherapy in pancreatic cancer (Galloway, Aspe et al. 
2009). Reduction of Survivin levels and/or inhibition of the protein’s anti-apoptotic prop-
erties may assist in making cancer cells more susceptible to existing (and future) 
therapeutic regimens. Successful strategies against intracellular Survivin include molecu-
lar antagonists such as antisense oligos, RNA inhibition, Survivin-specific cytolytic T 
cells, the nonphosphorylatable dominant negative Survivin mutant Thr34→ Ala (T34A), 
and most recently, binding interface mimetics (Olie, Simoes-Wust et al. 2000, Andersen, 
Pedersen et al. 2001, Grossman, Kim et al. 2001, Kanwar, Shen et al. 2001, Mesri, Wall 
et al. 2001, Wall, O'Connor et al. 2003, Plescia, Salz et al. 2005, Andersen, Svane et al. 
2007). 
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The loss of phosphorylation at the Survivin Thr34 site is significant as it results in 
the dissociation of the caspase-9/Survivin protein complex, leading to antitumor effects 
(Grossman, Kim et al. 2001, Peng, Yang et al. 2008, Li, Zhao et al. 2009, Shen, Liu et al. 
2009, Aspe and Wall 2010). Mesri, et al. employed Survivin-T34A treatment in vivo via 
adenoviral vectors, with their results yielding only modest levels of success (Mesri, Wall 
et al. 2001). A better delivery method will need to be utilized if this Survivin inhibitor is 
to prove efficacious in vivo. 
Conditioned media (CM) collected from cervical, pancreatic, prostate, breast can-
cer, osteosarcomas, leukemia cell lines (Khan, Aspe et al. 2009) and CM collected from a 
Survivin-T34A overexpressing HeLa cell line provided evidence that functional Survivin 
can be found extracellularly in the CM. We have recently shown extracellular Survivin to 
reside in small 50-100 nm vesicles called exosomes (Khan, Jutzy et al. 2011). Exosomes 
have been described as a pivotal mechanism in the multicellular organism for cell to cell 
communication as they allow for cells to exchange information through transferal of sol-
uable factors such as proteins, RNAs and miRNA (Bobrie and Thery 2013). More 
recently, exosomes have been exploited for cancer immunotherapy as there may be op-
portunity to adapt them as drug delivery vehicles for therapeutic intervention(S, Mager et 
al. 2013). The typical exosome is 50-100 nm in size and originates intracellularly, dis-
playing MHC class I and class II, heat shock proteins, tetraspanin proteins and in our 
hands inhibitor of apoptosis (IAP) proteins (Tan, De La Pena et al. 2010, Khan, Jutzy et 
al. 2011). 
We showed in this undertaking Survivin-T34A CM eliciting anticancer effects 
such as induced apoptosis with loss of mitochondrial potential. The goal of the present 
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study was to determine if the cells engineered to overexpress the Survivin-T34A domi-
nant-negative mutant would produce a functional, exosomally packaged, Survivin-T34A 
which when used in combination with Gemcitabine might significantly enhance the death 
of pancreatic cancer cells, in vitro. 
 
Materials and Methods 
Cell Cultures 
Pancreatic adenocarcinoma (MIA PaCa-2) cell line was obtained from the Ameri-
can Type Culture Collection (ATCC, Manassas, VA) and maintained in DMEM, 
supplemented with 100 units of penicillin, 100 g/mL streptomycin, 300 g of L-
glutamine, 10% heat inactivated FBS (ATCC), and 2.5% horse serum. Exosomes were 
isolated from YUSAC 2, a melanoma cell line obtained from Dr. Doug Grossman at the 
Huntsman Cancer Institute in Salt Lake City, Utah. The two cell line derivatives from 
YUSAC 2 were designed to overexpress either Survivin-WT (4C7 cells) or Survivin-
T34A (F5C4 cells) in the absence of tetracycline (tet), otherwise only normal endoge-
nous levels of Survivin are produced. YUSAC 2 cells were maintained in DMEM 
(CellGro, Manassas, VA) supplemented with 100 units of penicillin, 100 g/mL strep-
tomycin, 300 g of L-glutamine, 5% newborn calf serum (Thermo Scientific HyClone, 
Rockford, IL), 0.5 g/mL tetracycline (tet-off system), 1.5 mg/mL Geneticin G418 
(Teknova, Holister, CA), and 2 mM NaOH. YUSAC 2 cells were grown to 60% conflu-
ency in the presence of tetracycline in order to establish a healthy monolayer culture. 
Subsequently, cells were washed carefully twice in PBS followed by the addition of me-
dia in the absence of tetracycline. All cells were grown at 37 °C in a humidified 
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atmosphere containing 5% CO2. 
 
Gemcitabine Treatment 
Gemcitabine (Sigma-Aldrich, St. Louis, MO) was dissolved in DMSO and added 
to cells simultaneously with exosome treatment. Final DMSO concentration was 0.03%. 
Final Gemcitabine concentration used was 10 μM. The cells were returned to the incuba-
tor and harvested after 24, 48, or 72 hrs. for apoptosis analysis by flow cytometry. 
 
Exosome Isolation and Quantification 
Exosomes were isolated from conditioned media (CM) as we have previously re-
ported (Khan, Jutzy et al. 2011). In brief, the culture media was collected from cells in 
culture after 24 hrs.. The CM was centrifuged at 10,000 × g for 10 min at 4 °C to pellet 
the minor amounts of cells and cell debris. CM was filtered through 0.22 µm syringe fol-
lowed by centrifugation at 100,000 × g for 18 hrs. at 4 °C on a 30% sucrose cushion 
(Thery, Amigorena et al. 2006). The sucrose cushion containing exosomes was collected 
and washed with PBS followed by additional centrifugation at 100,000 × g for 18 hrs. at 
4 °C. Exosome pellets were collected and stored at -80 °C. Exosome quantification was 
accomplished using acetylcholinesterase assay, according to the protocol of Lancaster 
and Febbraio (Lancaster and Febbraio 2005). Briefly, acetylcholinesterase activity was 
employed to determine the presence of exosome vesicles. 40 µL of the exosome fraction 
was suspended in 110 µL of PBS. 37.5 µL of this PBS-diluted exosome fraction was then 
added to individual wells on a 96-well flat bottom plate. 112.5 µL of 1.25 mM acetylthi-
ocholine and 150 µL of 0.1 mM 5,5’-dithio-bis(2-nitrobenzoic acid) were added to PBS-
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diluted exosomes. The change in absorbance at 412 nm was monitored every 5 min for 30 
min. The data presented represents acetylcholinesterase enzymatic activity after a 30 min 
incubation. Exosome and whole cell lysate (WCL) protein was quantified using the BCA 
assay on a µQuant microplate spectrophotometer (Bio-Tek, Winooski, VT) and analyzed 
using KC Junior Software (Bio-Tek). 
 
Apoptosis and Cell Cycle Analysis 
Sub-confluent cultures of the pancreatic cancer cells were incubated with vehicle 
(DMSO), Gemcitabine (0 to 500 M) and/or exposed to exosomes treatment (0-1500 
g/mL total protein, exosomes were sterilized using 0.22µm syringe filter) for 0, 24, 48, 
and 72 hrs. at 37°C. Cells were harvested, prepared, and analyzed for DNA content using 
a Becton Dickinson FACScan flow cytometer (Becton Dickinson, San Jose, CA) as de-
scribed previously (Li, Ackermann et al. 1999, Khan, Jutzy et al. 2011). The distribution 
of cells in the different phases of the cell cycle was analyzed from DNA histograms using 
BD CellQuest software (Becton Dickinson and Company, San Jose, CA). 
 
Western Blot Analysis 
Whole cell lysates (WCLs) were prepared as previously described (Galloway, 
Aspe et al. 2009) and quantified as described above. Proteins (30 g) were separated us-
ing 12 or 15% Bis-Tris polyacrylamide gels and then transferred onto nitrocellulose 
membranes (Bio-Rad) and probed using 1-5 g/ml of the following antibodies: rabbit 
polyclonal anti-Survivin (Novus, Littleton, CO), rabbit anti-ppSurvivin-Thr34 (Novus), 
rabbit polyclonal anti-β-actin (BioLegend, San Diego, CA), and mouse polyclonal anti-
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LAMP-1 (Cell Signaling Technologies, Beverly, MA). Secondary antibodies (IR-Dye-
conjugated) were goat anti-rabbit and goat anti-mouse immunoglobulin (LI-COR, Lin-
coln, Nebraska) used at a 1:5000 dilution. Membranes were blocked for 1 hr. using 
blocking reagent purchased from LI-COR. Membranes were incubated overnight in pri-
mary antibody followed by three 15 minute PBS-Tween wash steps and a final 1 hour 
secondary antibody incubation followed again by three 15 minute PBS-Tween washings. 
Immunoreactive bands were detected using the Odyssey imaging system (LI-COR). β-
actin or LAMP-1 was used as Western blot loading controls for either cell lysates or exo-
somal protein, respectively. 
 
Statistical Analysis 
Multiple comparisons among different groups were calculated by using Multiple Analysis 
of Variance (MANOVA) as we have done in the past (Khan, Jutzy et al. 2012). Student t-
test (two-tailed) was used to evaluate the significance of changes between control groups 
and experimental groups. Probability values P<0.05 were considered statistically signifi-
cant. 
 
Results 
The Presence of Survivin-T34A Induces Time-dependent Apoptosis 
The melanoma cell line, YUSAC 2, was engineered to overexpress WT Survivin 
(4C7) or mutant T34A (F5C4), as previously reported (Grossman, Kim et al. 2001). The 
YUSAC 2 cells were continuously treated with 0.5 µg/mL of tetracycline (tet) to prevent 
overexpression of Survivin-WT (4C7 cells) or Survivin-T34A (F5C4 cells) in this tet-off 
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system. Cells were harvested 6, 12, 18 and 24 hrs. after removal of tet for analysis by 
Western blot and flow cytometry (Figure 19). Following tet removal, Survivin protein 
was concomitantly increased in both cell lines in a time-dependent manner (Figure 19A) 
as it has been previously reported (Grossman, Kim et al. 2001). Removal of tet from 
F5C4 cells resulted in increased apoptosis in a time-dependent manner, maximizing at 72 
hrs., while no increase in apoptosis was recorded in the 4C7 cells treated under the same 
conditions (Figure 19B). 
 
Survivin-T34A Overexpressing Cells Showed Decreased  
Phosphorylated Survivin in a Time- 
dependent Manner 
4C7 and F5C4 cells were incubated in either the presence or absence of tet for 24 
hrs., and levels of Survivin, phospho-Survivin and -actin were analyzed by Western 
blotting. 4C7 and F5C4 cells expressed increased Survivin levels in the absence of tet 
compared to tet-treated control cells (Figure 20). Survivin phosphorylation at Thr34 was 
confirmed by Western blotting using a phospho-specific Survivin Thr34 antibody as has 
been previously shown (Grossman, Kim et al. 2001). Tet-free F5C4 cells showed a de-
creased phospho-Survivin band compared to tet-free 4C7 cells.  
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Figure 19. (A) Western blots of whole cell lysates of YUSAC 2 cell line derivatives. 4C7 
or F5C4 cells were incubated in the presence or absence of tetracycline for 6, 12, 18, and 
24 hrs., which in the absence of tetracycline will overexpress Survivin-WT or Survivin-
T34A, respectively. Survivin is increased in a time-dependent manner when incubated in 
the absence of tetracycline. Beta-actin was used as the loading control and molecular 
weights (kDa) are shown on the left. Densitometry was undertaken to show the degree of 
Survivin increase. (B) Histogram representing the percentage of apoptosis using propidi-
um iodide (PI) analysis by flow cytometry, 4C7 show similar apoptosis levels for both 
tet-treated and tet-free conditions. F5C4 cells have increasing apoptosis in a time-
dependent manner when incubated in tet-free media. Data are the mean ± SD of three in-
dependent experiments (*p<0.05).  
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Figure 20. Western blot of whole cell lysates of YUSAC 2 cell line derivatives. 4C7 and 
F5C4 cells were incubated in the presence or absence of tetracycline for 24 hrs., which in 
the absence of tetracycline will overexpress wild-type or Survivin-T34A, respectively. 
4C7 has increased Survivin in absence of tetracycline, which is concurrent with phos-
phorylated Survivin-Thr34. However, in the absence of tetracycline F5C4 also 
overexpresses Survivin, but it is not phosphorylatable at the Thr34 site.  
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YUSAC 2 Cells Release Survivin-containing Exosomes 
In order to confirm that F5C4 cells release exosomes, we isolated exosomes by ul-
tracentrifugation using a sucrose cushion as has been previously described (Thery, 
Amigorena et al. 2006, Khan, Jutzy et al. 2011). Following ultracentrifugation, exosome 
levels were analyzed using the acetylcholinesterase enzyme (AChE) activity assay (Fig-
ure 21A). No significant difference in exosome levels between tet-treated and tet-free 
cells was measured at 24 hrs., signifying that the number of exosomes released is inde-
pendent of the tet-system. 
Exosomal Survivin content was evaluated by Western blotting. Survivin expres-
sion was elevated after tet removal in exosomes from both 4C7 and F5C4 cells (Figure 
21B). This was similar to observed levels of Survivin expression in whole cell lysates 
from YUSAC 2 cells. In order to evaluate Survivin-T34A presence in the exosomes re-
leased from F5C4 cells, we employed the phospho-specific Survivin Thr34 antibody for 
Western blots of these exosomes. Survivin was increased in the exosomes from tet-free 
F5C4 as was recorded in the immunoblots from the parent cells. However, there were no 
phosphorylated-Survivin bands from either exosomes of tet-treated or tet-free F5C4 cells 
(Figure 21C). The presence of tet-removal-enhanced Survivin, coupled with the absence 
of phosphorylated-Survivin, provides strong evidence that these exosomes contain the 
dominant-negative Survivin-T34A. 
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Figure 21. (A) Histogram representing an acetylcholinesterase enzyme activity assay to 
quantify exosome numbers relative to fresh complete media. Exosomes are present as 
represented by the graph when compared to control. There is no difference within the 
same cells when treated with tetracycline or without. Data are the mean ± SD of 3 inde-
pendent experiments. (B) Both YUSAC 2-derived cell lines overexpress Survivin in the 
absence of tetracycline. (C) Western blots of proteins isolated from exosomes collected 
from F5C4 cells after incubation in the presence or absence of tetracycline for 24 hrs.. 
LAMP-1 was used as the loading control with molecular weights (kDa) shown on the 
left.  
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Exosomes Containing Survivin-T34A Induce Apoptosis in  
MIA PaCa-2 Pancreatic Cancer Cells 
Exosomes isolated from tet-treated F5C4 (endogenous WT Survivin) cells were 
employed as the control for exosomes isolated from tet-free F5C4 cells (Survivin-T34A). 
There was no significant apoptotic induction (≤10%) after MIA PaCa 2 cells were treated 
with 200, 1000 or 2000 µg/mL of exosomes purified from tet-treated F5C4 cells after 24 
and 48 hrs. (Figure 22). MIA PaCa 2 cells were then treated using exosomes containing 
Survivin-T34A (150 and 750 µg/mL based on total exosomal protein). Results showed 
little apoptosis (~5%) versus treatment by control exosomes (from tet-treated F5C4 cells) 
at 24 hrs. (Figure 22). However, using Survivin-T34A exosomes (1500 µg/mL), a marked 
48 hrs. increase in apoptosis (30.5%) was measured. 
 
Survivin-T34A Exosomes Enhance Gemcitabine Treatment  
on Pancreatic Cancer Cells 
In order to investigate whether exosomes containing Survivin-T34A could en-
hance Gemcitabine-cytotoxicity, MIA PaCa 2 cells were treated with either exosomes 
containing Survivin-WT (200 µg/mL) or Survivin-T34A (150 µg/mL) or 10 µM Gem-
citabine. Gemcitabine dosage levels conformed to the protocols previously established in 
our laboratory (Galloway, Aspe et al. 2009). Exosome concentrations were chosen that 
did not induce a measurable level of apoptosis (Figure 22) at 24 and 48 hrs. as an induced 
additive or potentiative response from the combination was the goal. We also measured 
apoptotic cell death after pancreatic cancer cells were treated with a combination of exo-
somes and Gemcitabine. At 24 hrs., no marked differences  
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Figure 22. Histograms representing the percent apoptosis in MIA PaCa2 cells following 
exosome treatment for 24 and 48 hrs.. MIA PaCa 2 cells treated for 24 hrs. showed little 
to no increase in apoptosis after exosomes treatment. After 48 hrs. treatment, only 1500 
g/mL of exosomes containing Survivin-T34A induced apoptosis (30.5%). Percent apop-
tosis was determined from sub-G1 DNA content analyzing propidium iodide staining by 
flow cytometry. Data are the mean ± SD of 2 independent experiments. 
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Figure 23. MIA PaCa 2 cells were treated with either 10 M Gemcitabine, 150 or 200 
g/mL (total exosomal protein from F5C4), or the combination of both. MIA PaCa 2 
cells treated for 24 hrs. showed little to no marked increase in apoptosis (<5%) after exo-
somes treatment. 10 M Gemcitabine had modest apoptosis induction over control 
(~11% vs. 2%, respectively). The combination of 10 M Gemcitabine with 150 g/mL 
exosomes containing Survivin-T34A yielded 32% apoptosis (~30% greater than control) 
after 48 hrs. Percent apoptosis was determined from sub-G1 DNA content analyzing pro-
pidium iodide staining by flow cytometry. Data are the mean ± SD of 2 independent 
experiments (*p<0.05, **p<0.01). 
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between the various treatments (24 hrs., <4%) were recorded (Figure 23). As expected 
Gemcitabine induced modest apoptosis vs. control (10% and 2%, respectively) after 48 
hrs.. However, the combination of exosomes containing Survivin-T34A with 10 µM 
Gemcitabine treatment displayed the greatest enhanced apoptosis compared to control 
and the single modality treatments (32% apoptosis vs. less than 10% apoptosis) after 48 
hrs.. The combination treatment utilizing exosomes containing Survivin-T34A yielded 
the same levels of apoptosis as did treatment using 1500 µg/mL Survivin-T34A exo-
somes. 
 
Discussion 
We have previously described Survivin’s (WT and T34A) presence in the extra-
cellular conditioned media (Bokarewa, Lindblad et al. 2005, Mera, Magnusson et al. 
2008, Khan, Aspe et al. 2009, Khan, Jutzy et al. 2011), and that extracellular Survivin can 
be taken up by cancer cells resulting in functional effects such as proliferation, invasion 
and resistance (Khan, Aspe et al. 2009). We have also shown that Survivin is released via 
small membrane-bound vesicles called exosomes (Khan, Jutzy et al. 2011). Building up-
on these findings, we have sought to test whether or not exosomes containing the 
apoptosis-inducing Survivin mutant, T34A, could be produced and if so, used either 
alone or in combination with other treatment methods as a cancer therapeutic. 
To this end, the YUSAC 2 tet-off system (Grossman, Kim et al. 2001) was em-
ployed. Exosomes must be collected early so that the vesicles being harvested are intact 
and functional with the production of apoptotic bodies kept at a minimum. The F5C4 cell 
lines provide a good system in which the tet-off regulatory mechanisms allow for Sur-
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vivin-T34A to be controlled systematically in all cells. The released quantity of exosomes 
was independent of the tet-system, which is important because any changes in protein 
levels within the exosomes are the result of the tet-system and not the quantity of exo-
somes. Our results demonstrate for the first time that Survivin-T34A is released from the 
cells via exosomes. 
Utilizing exosomes for anticancer therapy an emerging and rapidly growing field 
(Khan, Jutzy et al. 2011). Dendritic exosomes (DEX) are the most commonly utilized ex-
osomes for such therapy (Zitvogel, Regnault et al. 1998, Wolfers, Lozier et al. 2001, 
Couzin 2005, Chaput, Flament et al. 2006, Tan, De La Pena et al. 2010). However, DEXs 
are typically used as a form of immunotherapy – a way to prime the immune system 
against tumor cells (Khan, Jutzy et al. 2011). Our aim in this study was to directly attack 
tumor cells with exosomes containing Survivin-T34A.  
MIA PaCa 2 cells treated in culture with exosomes containing Survivin-T34A un-
dergo enhanced apoptosis. When we compared Survivin-T34A exosome-induced 
apoptosis levels to that induced by Gemcitabine alone, 100 µM Gemcitabine yielded 50% 
less apoptosis in the pancreatic cancer cell lines PANC1 and MIA PaCa-2 (Galloway, 
Aspe et al. 2009) then did 1500 g/mL of Survivin-T34A-containing exosomes on the 
same cell lines. We could not obtain similar levels of apoptosis as exosomal Survivin-
T34A using our highest concentration of Gemcitabine (500 µM, data not shown). We 
therefore combined low doses of exosomal Survivin-T34A (150 µg/mL total protein) 
with Gemcitabine (10 µM) to investigate whether Survivin-T34A could enhance Gem-
citabine’s cytotoxic effects. Alone, these doses did not yield an increase in apoptosis over 
control. However, there was a marked enhancement of apoptosis when Survivin-T34A 
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exosomes and Gemcitabine were combined. Using 150 µg/mL of Survivin-T34A exo-
somes and 10 µM Gemcitabine, apoptosis levels reached greater than 30% after 48 hrs. of 
combined treatment. We believe the enhancement from the combination treatments oc-
curred because of the mechanism of Gemcitabine. Gemcitabine has been shown to reduce 
G2/M cell cycle arrest which reduces cellular Survivin levels (Aspe and Wall 2010). We 
also have found that a modest amount of stress induces wild-type Survivin in this model 
system (data not shown). This combined with Survivin-T34A exosomes, which target 
Survivin, enhances apoptosis with much lower dosages because it is believed that Sur-
vivin-T34A targets and disrupts Survivin-associated protection of the cancer cell (Blanc-
Brude, Mesri et al. 2003, Liu, Brouha et al. 2004, Aspe and Wall 2010). 
In summary, delivery has been the confounding factor for using the novel Sur-
vivin-T34A as an effective therapeutic. This study not only adds to the importance of 
using Survivin-T34A as a cancer therapeutic for the treatment of pancreatic cancer, but 
that exosome delivery may provide a potential mechanism for effective tumor delivery. 
Cancer research and therapy have been rapidly moving towards combinatorial therapies 
but clinically, Gemcitabine remains the most prominent player in effective pancreatic 
cancer therapy. In closing we would like to emphasize the importance of continued ex-
ploration of the potential of combining exosome delivery of Survivin-T34A with 
Gemcitabine and other anticancer therapeutic regimens. These studies may prove rele-
vance for the discovery and implementation of novel pancreatic cancer therapeutic 
strategies to improve the efficacy of chemotherapy-induced apoptosis in patients 
(Nicholson 2000). 
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CHAPTER FOUR 
CONCLUSION 
 
Our finding that Survivin, a unique human inhibitor of apoptosis (IAP), has inter-
cellular transport and signaling capabilities via exosomes is a significant and potentially 
seminal discovery. This led to another significant, potential discovery of Survivin-T34A 
being packaged into exosomes from genetically engineered YUSAC-2 cells which over-
express Survivin-T34A via a tet-off system. Consistent with Survivin’s association with 
unfavorable clinicopathological parameters, trafficking Survivin throughout the tumor 
microenvironment can drive the aggressive status of the tumor prohibiting or minimizing 
therapeutic results.  Thus, treatment of a tumor using Survivin-T34A induces apoptosis 
and sensitizes Gemcitabine induced cell death in MIA PaCA 2 cells. With the new dis-
covery that exosomes containing Survivin-T34A, taken from cells that overexpress 
Survivin-T34A, is able to kill cancer cells in vitro, we hope to further enhance the scien-
tific data banks and pave new paths for clinical modalities and regimens. Thus, the 
outcomes of this research project is significant to both cancer biology and clinical cancer 
research as a potentially novel cancer treatment. The knowledge that will make this pos-
sible includes: the elucidation of T34A target cell populations, cell-surface receptors, 
changes that occur in the target tissue at the molecular and cellular level, the mechanism 
of therapeutic action, and its site of action. Other potential future studies have also been 
described in Appendix A of this dissertation.  
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APPENDIX A 
FUTURE STUDIES 
 
Part 1:  To characterize the combinatorial therapy of exosomes with Gemcita-
bine in vivo to induce apoptosis and increase animal survival rates. 
Rationale 
Based on the project in this document, proof of concept in vitro has shown the po-
tential for enhancing the “Gold Standard” (Gemcitabine) for pancreatic cancer. Proof of 
concept in vivo is the next step. Because of the current poor prognosis for all pancreatic 
cancer patients, great strides to advance treatment of pancreatic cancer is essential. The 
novelty of this study is the delivery of exosomal based Survivin-T34A which may en-
hance Gemecitabine treatment while reducing toxicity. The objective of this study is to 
show proof of concept that exosomal Survivin-T34A enhances Gemcitabine treat-
ment in mice. To accomplish this project, SCID mice will be injected orthotopically into 
the pancreas with MIA PaCa 2 cells. Once the tumor has been established, treatment with 
exosomes and Gemcitabine will follow. Then, apoptosis, tumor size, and animal survival 
rates will be characterized. 
 
Part 2:  To characterize the mechanism by which Survivin-T34A causes release 
of Cytochrome c from the mitochondria inducing the intrinsic pathway 
of apoptosis as well as the possibility that Survivin through physical as-
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sociation with players within the intrinsic apoptotic pathway, inhibits or 
mediates this phenomenon. 
Rationale 
Proof of concept in vitro has revealed promising results, a logical next step is 
proof of mechanism. Currently, the intrinsic pathway of apoptosis involves Cytochrome 
c, which is known to be released from the mitochondria as well as other proapoptotic pro-
teins into the cytosol. Cytochrome c and cleaved Caspase-9 then bind to Apaf-1 to form 
the apoptosome therefore promoting caspase activation, PARP cleavage, and cell death.  
Phosphorylated Survivin-Thr34 is believed to the mechanism by which Cytochrome c is 
released into the cytosol is still unknown. Initially, Cytochrome c was thought to be re-
leased through mitochondrial membrane depolarization and mitochondrial permeability 
transition (MPT) - the result of the permeability transition pore (PTP). The PTP in the 
inner membrane opens and causes swelling of the matrix space, thus causing the outer 
membrane to rupture and spill Cytochrome c and other proapoptotic proteins into the cy-
tosol.  Recent studies using cyclophilin D knockouts have shown that PTP is primarily 
involved in necrosis and ischemia-reperfusion injury and less likely in intrinsic apoptosis 
and that Cytochrome c can be released in the absence of mitochondrial membrane depo-
larization. Instead, the mitochondrial apoptosis induced channel (MAC) has been 
proposed as the alternative mechanism by which Cytochrome c is released into the cyto-
sol. Following Cytochrome c release, Survivin has been speculated to directly inhibit 
caspases. Although several groups have reported that Survivin does not bind directly to 
Caspase-3, one group has shown a Survivin direct inhibition of both Caspase-3 and 
Caspase-7 through physical chemistry techniques. Only one study has reported that phos-
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phorylated Survivin-Thr34 can form a complex with Caspase-9 at midbodies and concom-
itantly inhibits apoptosis at cell division. From this we believe that Survivin physically 
associates with the apoptosome and directly inhibits cleaved Caspase-3 within the com-
plex. The objective of this study is to define the mechanism by which the 
phosphorylation status of Survivin-Thr34 inhibits or induces Cytochrome c release 
and its sequentially affected caspases. To accomplish this project, the use both 4C7 and 
F5C4 cell lines will be utilized to compare and contrast the subcellular localization of 
WT-Survivin and Survivin-T34A and their association with key mitochondrial factors. 
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